bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

RNA genome conservation and secondary
structure in SARS-CoV-2 and SARS-related
viruses
Ramya Rangan1, Ivan N. Zheludev2, Rhiju Das1,2,3*
1

Biophysics Program, Stanford University, Stanford CA 94305
Department of Biochemistry, Stanford University School of Medicine, Stanford CA 94305
3
Department of Physics, Stanford University, Stanford CA 94305
2

*Corresponding author: rhiju@stanford.edu

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

Abstract
As the COVID-19 outbreak spreads, there is a growing need for a compilation of conserved RNA
genome regions in the SARS-CoV-2 virus along with their structural propensities to guide
development of antivirals and diagnostics. Using sequence alignments spanning a range of
betacoronaviruses, we rank genomic regions by RNA sequence conservation, identifying 79 regions
of length at least 15 nucleotides as exactly conserved over SARS-related complete genome
sequences available near the beginning of the COVID-19 outbreak. We then confirm the
conservation of the majority of these genome regions across 739 SARS-CoV-2 sequences reported
to date from the current COVID-19 outbreak, and we present a curated list of 30 ‘SARS-relatedconserved’ regions. We find that known RNA structured elements curated as Rfam families and in
prior literature are enriched in these conserved genome regions, and we predict additional
conserved, stable secondary structures across the viral genome. We provide 106 ‘SARS-CoV-2conserved-structured’ regions as potential targets for antivirals that bind to structured RNA. We
further provide detailed secondary structure models for the 5´ UTR, frame-shifting element, and 3´
UTR. Last, we predict regions of the SARS-CoV-2 viral genome have low propensity for RNA
secondary structure and are conserved within SARS-CoV-2 strains. These 59 ‘SARS-CoV-2conserved-unstructured’ genomic regions may be most easily targeted in primer-based diagnostic
and oligonucleotide-based therapeutic strategies.

2

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

Introduction
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused a rapidly expanding
global pandemic, with the COVID-19 outbreak responsible at this time for over 600,000 cases and
25,000 deaths. The emergence of this pandemic has revealed an urgent need for diagnostic and
antiviral strategies targeting SARS-CoV-2. Like other coronaviruses, SARS-CoV-2 is a positive
sense RNA virus, with a large RNA genome approaching nearly 30 kilobases in length. Its RNA
genome contains protein-coding open reading frames (ORFs) for the viral replication machinery,
structural proteins, and accessory proteins. The genome additionally harbors various cis-acting RNA
elements, with structures in the 5´ and 3´ untranslated region (UTRs) guiding viral replication, RNA
synthesis and viral packaging.1 Conserved RNA elements offer compelling targets for diagnostics. In
addition, such RNA elements may be useful targets for antivirals, a concept supported by the recent
development of antisense oligonucleotide therapeutics and small-molecule RNA-targeting drugs for
a variety of targets across infectious and chronic diseases.2-4
Conserved structured RNA regions have already been shown to play critical functional roles in the
life cycles of coronaviruses. Most coronavirus 5´ UTR’s harbor at least four stem loops, with many
showing heightened sequence conservation across betacoronaviruses, and various stems
demonstrating functional roles in viral replication.5 Furthermore, RNA secondary structure in the 5´
UTR exposes a critical sequence motif, the transcriptional regulatory sequence (TRS), that forms
long-range RNA interactions necessary for facilitating the discontinuous transcription characteristic
to coronaviruses.6 Beyond the 5´ UTR, the frame-shifting element (FSE) in the first protein-coding
ORF (ORF1ab) includes a pseudoknot structure that is necessary for the production of ORF1a and
ORF1b from two overlapping reading frames via programmed ribosomal -1 frame-shifting.7 In the 3´
UTR, mutually exclusive RNA structures including the 3´ UTR pseudoknot control various stages of
the RNA synthesis pathway.8
Beyond these canonical structured regions, the RNA structure of the SARS-CoV-2 genome remains
mostly unexplored. Unbiased discovery of other conserved regions and/or structured regions in the
virus has the potential to uncover further functional cis-acting RNA elements. Here, we analyze RNA
sequence conservation across SARS-related betacoronaviruses and currently available SARS-CoV2 sequences, and we identify structured and unstructured regions that are conserved in each
sequence set; these intervals can provide starting points for a variety of diagnostic and antiviral
development strategies (Fig. 1). To identify structured regions, we predict maximum expected
accuracy structures around conserved regions and report the support of these single structures from
predictions of each RNA’s structural ensemble. We additionally identify thermodynamically stable
secondary structures across the whole genome, finding that currently known structures fall within
these predictions, but also identifying various new candidate structured regions. We pinpoint
unstructured genome intervals by identifying bases with low average base-pairing probabilities.
Finally, we present secondary structure models for key RNA structural elements of SARS-CoV-2
annotated in the betacoronavirus family.
Results
RNA sequence conservation in SARS-related betacoronaviruses and SARS-CoV-2
To identify potential regions of conserved RNA secondary structure in the virus, we located stretches
of the SARS-CoV-2 genome with high RNA sequence conservation across SARS-related
betacoronavirus full genome sequences. By identifying regions with high RNA sequence
conservation as a first step, we reasoned that we would be more likely to filter for functionally
relevant structures that must be conserved through virus evolution and thereby discover targets that
are potentially less likely to develop resistance against therapeutics or to escape diagnosis as the

3

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

virus evolves. To ensure reasonable numbers of sequences while still focusing on conservation and
structure patterns most relevant to the current pandemic, we chose to analyze not all
betacoronaviruses but a subgroup of SARS-related betacoronaviruses. These include SARS, SARSCoV-2, and SARS-related bat coronaviruses, but not MERS, MHV, or other betacoronaviruses which
have been classified into distinct subgroups based on different sequence and structure features in,
for example, their 5´ UTR’s.9
We carried out this analysis beginning with three different sequence alignments. Each captures a
range of complete genome sequences across the SARS-related betacoronviruses, but differ in the
total number of sequences and in the redundancy of those sequences, as follows:
1. The first multiple sequence alignment (SARSr-MSA-1) was computed by aligning sequences
curated by Ceraolo and Giorgi,10 filtered by including only the reference genome sequence
NC_0405512.211 from the SARS-CoV-2 sequence set, removing the two MERS sequences,
and leaving in all remaining betacoronavirus whole genome sequences. This alignment
captures a range of SARS-related bat coronavirus and SARS sequences with only 11
sequences. These sequences correspond well to the SARS-related group defined in
Gorbalenya, Baker, et al.12
2. The second MSA (SARSr-MSA-2) was obtained from BLAST by searching for the 100
complete genome sequences closest to the SARS-CoV-2 reference genome. This alignment
captures a larger set of SARS-CoV-2, SARS, and bat coronavirus sequences than SARSrMSA-1 but includes many sequences with high pairwise similarity.
3. The final MSA (SARSr-MSA-3) was obtained by locating all complete genome
betacoronavirus sequences from the NCBI database, and removing mutually similar
sequences with a 99% sequence conservation cutoff. With 180 sequences with at most 99%
pairwise sequence similarity, this MSA captures a broader set of betacoronaviruses than
SARSr-MSA-1 and SARSr-MSA-2 but is more challenging to align due to higher sequence
diversity.
We computed conserved regions as contiguous stretches of 15 nucleotides or longer that were
100% conserved (cutoff for SARSr-MSA-1), 98% conserved (cutoff for SARSr-MSA-2), or 54%
conserved (cutoff for SARSr-MSA-3). Searching for conserved regions of 15 nucleotides or more
enables the design of antisense oligonucleotides that fall within these stretches. The sequence
conservation cutoffs chosen ensured that at least 75 candidate conserved stretches were used for
further structure analysis for each MSA. When calculating sequence conservation at the 5´ and 3´
sequence ends of the sequence, we did not include sequences that included only leading or trailing
sequence deletions up to that point to avoid sequencing artefacts.
In Fig. 2, we depict conserved regions (100% conservation cutoff, SARSr-MSA-1) alongside the
genome coordinates for the reference SARS-CoV-2 sequence. We observe intervals of conservation
in the 5´ UTR and 3´ UTR genome regions, as expected based on prior work demonstrating
sequence conservation surrounding structured RNA elements in these regions,13 but we also noted
stretches of RNA sequence conservation within some viral ORFs.
Interestingly, in SARSr-MSA-1 and SARSr-MSA-2 we found that conserved stretches overlapped
with previously curated Rfam14 families for Coronaviridae RNA secondary structures: the
frameshifting stimulation element (Rfam family RF00507), the 3´ UTR pseudoknot (Rfam family
RF00165), and the 3´ stem-loop II-like motif (Rfam family RF00164) (Fig. 2). Locations for the
frameshifting stimulation element, 3´ UTR pseudoknot, and 3´ stem-loop II-like motif were confirmed
using Infernal,15 with all regions discovered at an E<10-4 threshold. We also found overlap between
conserved stretches and additional 5´ UTR structures that have been established for previous
coronaviruses, including the original SARS virus, including stem loops 2-3 (SL2-3) and stem loop 5
(SL5).16 These five known RNA structures overlap with conserved regions more than expected; in

4

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

10,000 random trials, the chance that five randomly chosen intervals of these lengths all overlap with
the conserved regions from SARSr-MSA-1 or SARSr-MSA-2 is less than 0.0003. The enrichment of
known RNA structures in these conserved regions suggests that other conserved regions may also
harbor RNA structures.
To further tighten this list of conserved sequences to ones most relevant to the current COVID-19
outbreak, we analyzed whether sequence regions conserved across SARS and bat coronaviruses
remain conserved in the SARS-Cov-2 strains, most of which emerged after our analysis above (Fig.
1A). We determined the conservation of conserved genome regions from SARSr-MSA-1 across
SARS-CoV-2 sequences as of deposition date 03-18-20. For this analysis, we obtained two wholegenome multiple sequence alignments, keeping only full-length genome sequences of at least
29,000 nucleotides in both cases: the first includes 103 NCBI sequences (SARS-CoV-2-MSA-1),
and the second includes 739 sequences deposited to GISAID17 (SARS-CoV-2-MSA-2). We noted
conserved regions in the betacoronavirus alignment SARSr-MSA-1 were more likely to be at least
99% conserved in both SARS-CoV-2-MSA-1 and SARS-CoV-2-MSA-2 than random intervals of the
same size (binomial test p-value < 1e-5). Table 1 lists these regions, which we term the SARSrelated-conserved regions. These genome regions are conserved across the betacoronavirus
sequences in SARSr-MSA-1 and have at least 99% sequence conservation across whole-genome
sequences from the SARS-CoV-2 outbreak as of March 18, 2020 (SARS-CoV-2-MSA-2).
Conservation percentages for SARSr-MSA-1, SARSr-MSA-2, SARS-CoV-2-MSA-1, and SARS-CoV2-MSA-2 are included in Supplementary File 1. We expect that some diagnostic and therapeutic
strategies will benefit from focusing on conserved regions across a broad range of
betacoronaviruses, whereas others may benefit from focusing on regions conserved only in SARSCoV-2; we revisit the latter category of SARS-CoV-2-unique regions below.
Predictions for structured regions in SARS-CoV-2
The intrinsic RNA structure of a conserved genome region is of interest in current medical research
(Fig. 1B). On one hand, stable secondary structure domains are candidates for harboring
stereotyped 3D RNA folds that present targets for small-molecule drug therapeutics. On the other
hand, if an RNA region is sufficiently unstructured to allow binding by hybridization probes, antisense
oligonucleotides may be used to disrupt these functional structures. Such unstructured stretches
may also be more likely to be accessible to diagnostic and antiviral interventions including standard
RT-PCR assays.
We used two approaches to make predictions for conserved structured regions in SARS-CoV-2.
First, we predicted RNA structures centered on the most sequence-conserved regions of SARSrelated betacoronavirus genomes (alignment SARSr-MSA-1). For each conserved stretch (at least
15 nucleotides long, 100% sequence conservation) along with 20 nucleotide flanking windows, we
predicted maximum expected accuracy (MEA) secondary structures using Contrafold 2.0.18 We then
sought to rank sequences based on the predicted probability that the RNA folds into the MEA
structure and not other structures. For this ranking, we used the estimated Matthews correlation
coefficient (MCC) from each construct’s base-pairing probability matrix.19 We note here that while
MCC is often used in the RNA structure modeling literature to assess agreement of a prediction with
a reference structure, we here use the metric to assess how tightly concentrated the ensemble of
predicted secondary structures is to a single predicted secondary structure, the MEA structure. An
MEA structure with a higher estimated MCC is expected to have unpaired and paired bases that
better align with the construct’s predicted ensemble base-pairing probabilities, lending support to the
single-structure MEA prediction. In Fig. 2 regions A-E, we display the five conserved regions with the
top maximum expected accuracy (MEA) secondary structures as ranked by the estimated MCC (all
regions listed in Supplementary File 1). Regions D and E occurred within the 5´ UTR and correspond
to known SARS-related virus stem loops SL5a and SL2, respectively. Interestingly, region A is close

5

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

to but does not overlap with the frameshifting stimulation element; it lies 200 nucleotides
downstream of the FSE and could perhaps be involved in a more elaborate structure, as has been
described for human coronavirus 229E and other coronaviruses.20
We also sought independent methods to identify thermodynamically stable and conserved RNA
structures, without initially guiding the search to focus on extremely sequence-conserved genome
regions. We made predictions for structured regions using RNAz21, beginning with the
betacoronavirus alignment SARSr-MSA-1. RNAz predicts structured regions that are more
thermodynamically stable than expected by comparison to random sequences of the same length
and sequence composition (z-score), and additionally assesses regions by the support of
compensatory and consistent mutations in the sequence alignment (SCI score). These two criteria
are combined into a single P-score, which when tested empirically on a set of ncRNAs produced a
false-positive rate of 4% at a P>0.5 cutoff and 1% at a P>0.9 cutoff. To predict structured regions
across the full viral genome, we scanned the SARSr-MSA-1 alignment in windows of length 120
nucleotides sliding by 40 nucleotides, predicted all RNAz hits in the plus strand at a P>0.5 cutoff,
clustered the resulting hits to generate maximally contiguous loci of the genome with predicted
structure, and filtered results to only include loci with at least one window with a P>0.9 structure
prediction.
The RNAz approach led to the prediction of 44 structured genome loci comprising 117 windows with
predicted structure (P>0.9), with these loci covering 46% of the SARS-CoV-2 genome (Figure 3). We
found that five canonical RNA structures (the frameshifting element, the 3´ UTR pseudoknot, the 3´
UTR hypervariable region, 5´ UTR SL2-3, and 5´ UTR SL5) were present in these loci. Additionally,
conserved SARS-CoV-2 regions overlap significantly with predicted RNAz loci, with 62 of 78 SARSCoV-2 conserved intervals at a 97% sequence cutoff overlapping by at least 15 nucleotides with
RNAz loci. This enrichment is statistically significant (p-value<0.001 from comparisons to 10,000
random placements of conserved intervals). This enrichment also holds when considering overlaps
with conserved regions from SARSr-MSA-1; 124 of the 229 SARSr-MSA-1 conserved intervals at a
90% conservation cutoff overlap by at least 15 nucleotides with RNAz loci (p-value 0.0038). This
analysis potentially expands the set of conserved structural regions of SARS-CoV-2 beyond known
Rfam families and those noted in the literature (full set of RNAz loci in Supplementary File 1). Topscoring structured windows from RNAz that overlap with conserved sequence regions in SARS-CoV2-MSA-2 for at least 15 nucleotides are included in Table 2; we termed these SARS-CoV-2conserved-structured regions. Overlapping intervals between the RNAz predictions and conserved
sequence regions in SARSr-MSA-1 are included in Supplementary File 1.
We sought to further check structured windows reported by RNAz using orthogonal approaches.
First, we explored using R-scape to make structure predictions with covariation signal in the
sequence alignments. However, we found that the SARSr-MSA-1 alignment had insufficient variation
to detect conserved base pairs with covariation, lacking alignment power for all genomic windows.22
Second, we validated structured window predictions with alifoldz, a program that calculates a zscore for an alignment window by comparing the window’s consensus minimum free energy
structure to that of random shuffled alignments. To mirror the RNAz analysis above, we scanned
through windows of length 120 nucleotides sliding by 40 nucleotides. We chose a z-score cutoff of 2.69, which kept only 1% of windows when running alifoldz on all shuffled windows across the
genome. This approach led to predicting 228 alifoldz structured windows, overlapping with 104 of the
117 RNAz structured windows (P>0.9 cutoff). This overlap is statistically significant (p-value<1e-05).
RNAz structured windows supported by alifoldz analysis are highlighted in Supplementary File 1.
Conserved unstructured regions of SARS-CoV-2
We additionally located conserved regions of the viral genome predicted to lack structure, as such
regions may be desired targets for some diagnostic and therapeutic approaches (Fig. 1C). We

6

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

scanned the SARS-CoV-2 reference genome in windows of length 120 nucleotides sliding by 40
nucleotides, and for each window, we predicted the base-pair probability matrix with Contrafold 2.0,
using these probabilities to assemble average single-nucleotide base pairing probabilities across the
genome. In Figure 3, we display the 76 stretches of the genome of length at least 15 nucleotides
where every base has average base-pairing probability at most 0.4.
It is interesting to note that some structured 120 nucleotide windows reported by RNAz include these
unpaired stretches. A potential explanation for this observation is that such regions encode for welldefined, conserved RNA structures that themselves harbor long unpaired loops to recruit proteins,
distal RNA elements, or other molecular machinery.
Overall, we find that 58 of these unpaired stretches have at least 15 nucleotides of overlap with
sequence regions that are at least 97% conserved in SARS-CoV-2-MSA-2 (Fig. 5). These unpaired
stretches termed SARS-CoV-2-conserved-unstructured regions are listed in Table 3 (overlaps with
SARSr-MSA-1 are included in Supplementary File 1.)
As an orthogonal check for the unstructured intervals predicted using Contrafold 2.0 base-pairing
probabilities, we used Vienna’s RNAplfold to compute unpaired probabilities for each genome
position. In general, we found that RNAplfold predicted lower unpaired probabilities than Contrafold
2.0, with only 10 intervals of length at least 15 nucleotides having at least 0.6 probability of being
unpaired, in contrast with the 76 stretches predicted by Contrafold 2.0. Nevertheless, we found that
9 of the 10 intervals predicted by Vienna’s RNAplfold overlap with unpaired intervals predicted from
our Contrafold 2.0 analysis (regions listed in Supplementary File 1.)
Secondary structure models for canonical structured regions of SARS-CoV-2
Currently known RNA structures that recur across betacoronaviruses provide potential starting
points for therapeutic development targeting the SARS-CoV-2 RNA genome. Here, we include
secondary structures for the 5´ UTR (Figure 4a), frame-shifting element (Figure 4b), and 3´ UTR
(Figure 4c) for SARS-CoV-2, built by analyzing homology to literature-annotated structures in related
betacoronaviruses. We additionally include computer-readable secondary structures in Table 4 and
Supplementary File 1. A brief review of salient secondary structure features in these regions and
their putative functional roles in the betacoronavirus life cycle follows.
The 5´ UTR includes five confident stem-loop structures (SL1-SL5), with structures verified by
chemical mapping experiments in related coronaviruses.9, 16 SL1 and SL2 are conserved across
betacoronaviruses, with SL2 having the highest sequence conservation across the 5´ UTR.13 The
high A-U base-pairing content in the SARS-CoV-2 SL1 sequence and the bulged nucleotides align
with prior reports that SL1 is relatively thermodynamically unstable to allow for the formation of longrange interactions.23 SL2 has been shown to be critical for subgenomic RNA synthesis, with
mutations in its conserved pentaloop retaining the production of genome-sized RNA, but not
subgenomic RNA segments.24 SL3, conserved only in betacoronaviruses, presents the transcriptionregulating sequence (TRS) that base pairs with one of several complementary sequences in nascent
negative-sense strands in a ‘copy-choice mechanism’ that gives rise to discontinuous transcription of
subgenomic mRNAs.6 SL4 contains a short upstream ORF, here labeled uORF, which precedes the
first longer ORF1ab of the genome. The uORF leads to attenuated transcription of ORF1ab that
appears helpful but is not essential for viral replication.13 SL5 has been implicated in a potential role
in viral packaging, and contains the AUG start codon for long ORF1ab which encodes the viral
replicase/transcriptase polyprotein. The SARS-CoV-2 SL5 domain has common features with the
domain in other group IIb betacoronaviruses, for instance including UUCGU pentaloops on SL5a
and SL5b, and a GNRA tetraloop on SL5c.9 Prior DMS-probing data for Stem 5 in SARS-CoV
aligned with the proposed SL5a,b,c structures.9 Two additional stems (SL6 and SL7) are predicted

7

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

from computer modeling here, but prior literature has not established whether such stems embedded
in the coding region are functionally important across betacoronaviruses.
The frameshifting element (FSE) is located in ORF1ab and is involved in regulating a (-1) ribosomal
frameshift event that is necessary for producing ORF1b. The FSE consists of a conserved
pseudoknot structure that regulates the rate of ribosomal frameshifting at an upstream slippery site.7
This domain is nearly exactly conserved between SARS-CoV and SARS-CoV-2, suggesting a
similar mechanism for ribosomal pausing and slippage between the two viruses.25
The 3´ UTR contains various domains critical for regulating viral RNA synthesis and potentially
translation. The most 5´ region of the 3´ UTR includes a switch-like domain involving mutually
exclusive formation of a pseudoknot and stem-loop, both of which are essential for viral replication
with putative roles in establishing the kinetics of RNA synthesis.6, 26 The hyper-variable region
(HVR) is not essential for viral RNA synthesis, as this can be removed while allowing for viral
replication in tissue culture; however, viruses without this domain have lower pathogenicity in mice.27
This domain contains a completely conserved octonucleotide sequence with unconfirmed functional
significance. The stem-loop II-like motif (s2m) is another subregion of the HVR that is conserved in
SARS-CoV-2 and other coronaviruses. A crystal structure of the SARS s2m domain has been shown
to be homologous to an rRNA loop that binds translation initiation proteins, leading this domain to
have a proposed role in recruiting host translational machinery.28 The domain has been proposed to
be a selfish element due to its recurrence in numerous virus families outside the Coronaviridae, but
its function is not well understood.29
Discussion
Understanding the RNA structure of the SARS-CoV-2 genome can guide RNA-targeting
interventions and diagnostics. Here we have presented an initial analysis of RNA sequence
conservation across betacoronaviruses and current SARS-CoV-2 sequences, predictions for
structured and unstructured domains of the viral RNA genome, and homology-derived secondary
structure models for classic structured elements of the SARS-CoV-2 genome: the 5´ UTR, the
frame-shifting element, and the 3´ UTR. By filtering for sequences that have more than one of these
properties, we have curated three sets of RNA genomic regions of potential interest for further
structural analysis, which we have termed the SARS-related-conserved, SARS-CoV-2-conservedstructured, and SARS-CoV-2-conserved-unstructured sets. Fig. 5 gives a more extensive
presentation of how these sets overlap. Our hope is that these steps will provide useful starting
points for efforts to develop antivirals and diagnostics that depend on targeting either structured or
unstructured viral genomic regions.
The abundant RNA structures involved in the replication cycle of betacoronaviruses present ample
opportunities for therapeutic development, but our analysis is not complete. First, while homology to
prior structures annotated in betacoronaviruses lends some confidence to the 5´ UTR, frame-shifting
element, and 3´ UTR secondary structures presented here, there may still be some inaccuracies.
For instance, SL6 and SL7 in the 5´ UTR are built based on computer modeling. As another
example, the frame-shifting element structure presented here differs in two base pairs compared to
that presented by Kelly and Dinman.25 Additional biochemical and genetic verification, particularly
through compensatory mutagenesis, will be needed to further assess these structures.
Beyond the secondary structures highlighted here, prior work has pinpointed a variety of RNA-RNA
interactions important to the betacoronavirus life cycle. Long-range interactions between the 5´ UTR
and 3´ UTR have been implicated in RNA synthesis, for instance with mutations in the 5´ UTR SL1
only supporting viral replication when co-evolving with specific mutations in the 3´ UTR.13, 30 Such
long-range RNA-RNA interactions would be missed in our analyses above which have focused on

8

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

shorter windows. In related coronaviruses, RNA structures that act as packaging signals have been
identified in genomic ORFs.13 Such packaging signals may reside in regions identified here from our
RNAz computational analysis or may have been missed.
We believe a more thorough structure/function analysis of the virus should be obtainable with recent
experimental technologies that integrate multidimensional chemical mapping, electron microscopy,
and computer modeling.31-32 New candidates for structured RNA elements in SARS-CoV-2 could
play various functional roles, perhaps regulating viral packaging, replication, RNA synthesis, or
translation initiation. To further improve these structure predictions, information about protein-binding
events should be integrated, and biochemical assays can be conducted with these proteins present
or even in cells. Accounting for protein-binding events will be critical to completing a picture of
accessible and structured RNA sites.
The secondary structures predicted here present a reasonable starting point for 3D modeling of
RNA-only structures in various regions, including the 5´ UTR stem loop 5, the frame-shifting
element, the 3´ UTR pseudoknot, and the 3´ stem-loop II-like motif. Furthermore, these regions and
novel predicted structures can serve as candidates for RNA-only structure determination. Such 3D
structures have the potential to reveal well-defined 3D folds with conserved binding domains for
small-molecule drugs, potentially presenting alternative approaches for targeting SARS-CoV-2.
Methods
Conservation analysis
Three alignments for SARS-related viruses were prepared:
1. SARSr-MSA-1 was generated by re-aligning the sequences curated by Ceraolo and Giorgi10
with MUSCLE33 using default alignment settings, excluding all non-reference genome copies
of the SARS-CoV-2 sequence and excluding MERS sequences JX869059.2 and
KT368829.1.
2. SARSr-MSA-2 was generated by downloading the MSA provided by BLAST for the top 100
complete genome sequences closest to the SARS-CoV-2 reference genome.
3. SARSr-MSA-3 was generated by obtaining all complete betacoronavirus genome sequences
available from the NCBI database, removing mutually similar sequences using a 99% cutoff
with CD-HIT-EST34, and computing an MSA with Clustal Omega35 using default settings.
Two alignments for SARS-CoV-2 sequences were prepared:
1. SARS-CoV-2-MSA-1 was generated by downloading the MSA provided by NCBI for the 103
whole-genome SARS-CoV-2 sequences deposited as of 03-18-20.
2. SARS-CoV-2-MSA-2 was generated from 739 GISAID17 sequences, including all sequences
described in the Nextstrain project metadata file as of 03-18-20
(https://github.com/nextstrain/ncov). Sequences were aligned using MAFFT36 with the --add
flag to add GISAID sequences to seed alignment SARS-CoV-2-MSA-1, and the sequences
in SARS-CoV-2-MSA-1 were subsequently removed to avoid duplicates.
All alignments are included in the associated GitHub repository:
https://github.com/DasLab/SARSCoV2_Secstruct_Cons.
Analysis of structured elements
To identify regions in the SARS-CoV-2 reference genome NC_0405512.211 that were matches to
Rfam14 families, we used Infernal15 to build covariance models from Rfam families RR0164,
RR0165, and RR0507 with cmbuild, and we ran cmscan to find hits with an E<1e-04 threshold.

9

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

MEA structures were computed using Contrafold 2.018 for 20 nucleotide flanking windows around
conserved intervals in SARS-CoV-2. To estimate the Matthews correlation coefficient of these
single-structure predictions, we computed the pseudo-expected Matthews correlation coefficient as
described in Hamada, et al.19 Base-pairing probability matrices were computed Contrafold 2.0, and
these were then used to calculated the expected number of true positive, true negative, false
positive, and false negative base pairs. These computations were carried out using the Arnie
package (https://github.com/DasLab/arnie).
RNAz21 structures were predicted in windows of the SARS-CoV-2 genome using the SARSr-MSA-1
alignment. We used rnazWindow.pl to compile alignment windows across SARSr-MSA-1 with at
least 4 sequences in each window, using a window size of 120 nucleotides sliding by 40 nucleotides,
and using default settings otherwise. RNAz hits were computed at the P>0.5 threshold for the
forward strand with z-scores computed without a shuffled sequence background for efficiency, using
the --no-shuffle flag. The resulting RNAz structured windows were then clustered with rnazCluster.pl,
filtered with rnazFilter.pl at a P>0.9 threshold, and sorted with rnazSort.pl.
We ran alifoldz37 on the same genome windows used with RNAz above, again using SARSr-MSA-1.
The alifoldz z-score computations were calculated for the forward strand only with alifoldz.pl. We
additionally calculated alifoldz z-scores for alignment windows that were shuffled with shuffle-aln.pl
to assess background z-scores, determining that 1% of shuffled alignment z-scores were less than
-2.69.
We computed alignment powers with R-scape38 to assess the potential for using SARSr-MSA-1 for
covariation analysis. We generated Stockholm alignment files with biopython39 for windows of 120
nucleotides each sliding by 40 nucleotides. For each window, we ran R-scape with the –fold flag to
predict new structures, obtaining estimates for the power of each base pair in the predicted structure
(here, power is the expected sensitivity for detecting base pairs given the number of substitutions in
the alignment at that base pair). We then averaged across base pairs in each structure to obtain the
alignment power as described in Rivas, et al.,22 noting that all windows’ alignment powers fell below
the 0.10 threshold used by Rivas, et al.22 to distinguish low-power from high-power alignments.
Analysis of unstructured elements
To obtain probabilities that each genome position in SARS-CoV-2 was unpaired, we computed basepairing probability matrices with Contrafold 2.018 in windows of 120 nucleotides sliding by 40
nucleotides, and for each genome position, we summed the probabilities of pairing with all potential
partners. We then averaged these nucleotide pairing probabilities across all windows that nucleotide
was present in. Additionally, RNAplfold40 was run with window size 120 nucleotides, producing
another set of unpaired probabilities for each position in the genome.
Code and data availability
Code used for the conservation, structured, and unstructured analyses above can be found at the
GitHub repository: https://github.com/DasLab/SARSCoV2_Secstruct_Cons. The repository
additionally includes alignment files, Rfam families and covariance models, and output from the
RNAz, R-scape, alifoldz and RNAplfold analyses.
Acknowledgments
The authors acknowledge support from the National Science Foundation Graduate Research
Fellowship Program under grant no. 1650114 (R.R.), a Stanford Graduate Fellowship (I.N.Z.), and

10

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

NIH grant MIRA R35 GM122579 (to R.D.). We would like to thank Dr. Rachel H. Saluti, Dr. Edward
A. Pham, and Dr. Jeffrey S. Glenn for providing advice on the conserved, structured intervals
desirable for antisense oligonucleotide design; Hannah Wayment-Steele for useful discussions on
secondary structure modeling; Andrew M. Watkins for updates to the RiboDraw software for
rendering secondary structures; and Dr. Paul Gardner for providing rapid reviews of the initial
preprint of this manuscript on bioRXiv.

11

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

Figures

Figure 1: We aim to provide a series of genome regions in SARS-CoV-2 that are useful for a variety
of diagnostic and therapeutic strategies, including regions that are (A) conserved in SARS-related
betacoronaviruses and SARS-CoV-2 sequences (Table 1), (B) regions that are structured and
conserved in SARS-CoV-2 sequences (Table 2), and (C) regions that are unstructured and
conserved in SARS-CoV-2 sequences (Table 3).

12

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

Figure 2: In black we annotate SARSr-MSA-1 conserved regions of the genome, superimposed on
SARS-CoV-2 genome ORFs. We depict the top secondary structures as ranked by Matthews
correlation coefficient that overlap with these conserved regions, ordered from A to E. Regions A to
E are annotated on the genome in yellow and are located at genome positions: A:13743-13798,
B:17511-17566, C:28990-29054, D:172-236, E:26-109. Secondary structures are colored by
sequence conservation in SARSr-MSA-1 (cyan = more conserved, purple = less conserved). In
magenta are depicted curated Rfam families present in coronaviruses, including the frame-shifting
element (FSE), the 3´ UTR pseudoknot (PK3), and the 3´ stem-loop II-like motif (s2m). Figures
prepared in Geneious41 and draw_rna (https://github.com/DasLab/draw_rna).

13

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

Figure 3: Structured (cyan) and unstructured (yellow) intervals on the genome ORFs for SARS-CoV2, predicted from RNAz and a Contrafold 2.0 analysis, respectively. (A-C) highlight the three
secondary structures for windows that do not overlap with known Rfam or literature-annotated
structures with the highest P-value scores from RNAz (all P>0.9). These windows are located at
genome positions 14207-14366 (A), 17126-17245 (B), and 26176-26295 (C). Secondary structures
are colored by sequence conservation (cyan = more conserved, purple = less conserved). Figures
prepared in Geneious41 and draw_rna (https://github.com/DasLab/draw_rna).

14

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

15

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

Figure 4. Secondary structure diagrams for A) 5´ UTR, B) Frameshift element, C) 3´ UTR.
Nucleotides are black if 100% conserved in the SARS, bat, and SARS-CoV-2 sequences in SARSrMSA-1, and grey otherwise. Special labeled domains are in boldface. Structures are based primarily
on manual identification of homology with literature coronavirus structure models. Note that
numbering in (C) is relative to 3´ end of virus sequence. Figures prepared in RiboDraw
(https://github.com/ribokit/RiboDraw).

Figure 5. We depict the predicted number of structured, unstructured and conserved intervals for a
choice of sequence conservation cutoffs. The SARS-related conserved intervals are all regions of at
least 15 nucleotides with each position at least 90% conserved across an alignment of SARS, bat
coronavirus, and SARS-CoV-2 sequences (SARSr-MSA-1). The SARS-CoV-2 intervals are regions
of at least 15 nucleotides with each position at least 97% conserved across an alignment of currently
available SARS-CoV-2 sequences (SARS-CoV-2-MSA-2). Structured intervals are loci predicted
from RNAz with some loci containing multiple RNAz windows, and unstructured intervals are
stretches of at least 15 nucleotides where all bases have base-pairing probability at most 0.4. All
interval intersections are required to have at least 15 nucleotide overlaps, with the number of
overlapping intervals listed for each interval type involved in the intersection. Top-scoring structured
intervals conserved in SARS-CoV-2 sequences (green) are listed in Table 2. Top-scoring
unstructured intervals conserved in SARS-CoV-2 sequences (blue) are listed in Table 3.

16

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

Name

Interval

SARS-related-conserved-1

14060-14075

SARS-related-conserved-2

15838-15857

SARS-related-conserved-3

28554-28569

SARS-related-conserved-4

28513-28546

SARS-related-conserved-5

16153-16169

SARS-related-conserved-6

27183-27212

SARS-related-conserved-7

27165-27181

SARS-related-conserved-8

25511-25530

SARS-related-conserved-9

25393-25409

SARS-related-conserved-10

12905-12924

SARS-related-conserved-11

13346-13361

SARS-related-conserved-12

15496-15518

SARS-related-conserved-13

28799-28818

SARS-related-conserved-14

27457-27473

SARS-related-conserved-15

25547-25562

SARS-related-conserved-16

17089-17105

SARS-related-conserved-17

17956-17975

SARS-related-conserved-18

18034-18050

SARS-related-conserved-19

704-723

SARS-related-conserved-20

25376-25392

SARS-related-conserved-21

10406-10422

SARS-related-conserved-22

16364-16388

SARS-related-conserved-23

15622-15644

SARS-related-conserved-24

15349-15367

SARS-related-conserved-25

15301-15323

SARS-related-conserved-26

14077-14099

SARS-related-conserved-27

741-756

SARS-related-conserved-28

25106-25128

SARS-related-conserved-29

26232-26267

SARS-related-conserved-30

28270-28293

Sequence
UAGAUAAUCAAGAUCU
UGGACUGAGACUGACCUUAC
UUCGUGGUGGUGACGG
AGAUGACCAAAUUGGCUACUACCGAAGAGCUACC
GUUAUGCUUACUAAUGA
GUACAGUAAGUGACAACAGAUGUUUCAUCU
GACAAUAUUGCUUUGCU
CACUCCCUUUCGGAUGGCUU
AUGGAUUUGUUUAUGAG
AGGUUUGUUACAGACACACC
GUGGGUUUUACACUUA
ACAACUGCUUAUGCUAAUAGUGU
AGCAGAGGCGGCAGUCAAGC
GAGUGUGUUAGAGGUAC
UUCUUGCUGUUUUUCA
GGUACUGGUAAGAGUCA
UGCAUAAUGUCUGAUAGAGA
UUACAAGCUGAAAAUGU
GACGAGCUUGGCACUGAUCC
UACACAUAAACGAACUU
UACAAUGGUUCACCAUC
UGUCUGUUAAUCCGUAUGUUUGCAA
UAUGAGUGUCUCUAUAGAAAUAG
GUUCUUGCUCGCAAACAUA
AAAUGUGAUAGAGCCAUGCCUAA
AAUGGUAACUGGUAUGAUUUCGG
AAAACUGGAACACUAA
GAAAUUGACCGCCUCAAUGAGGU
UGAGUACGAACUUAUGUACUCAUUCGUUUCGGAAGA
UAAAAUGUCUGAUAAUGGACCCCA

Conservation in
SARS-CoV-2
0.995896
0.995896
0.995868
0.995868
0.994528
0.99449
0.99449
0.99449
0.99449
0.99316
0.99316
0.99316
0.993113
0.993113
0.993113
0.991792
0.991792
0.991792
0.991792
0.991736
0.990437
0.990424
0.990424
0.990424
0.990424
0.990424
0.990424
0.990358
0.990358
0.990358

Table 1: SARS-related-conserved. Conserved regions across SARSr-MSA-1 and SARS-CoV-2MSA-2. All intervals are at least 90% conserved across the SARS and bat coronavirus sequences in
SARSr-MSA-1, have length at least 15 nucleotides, and have every position at least 99% conserved
in current GISAID SARS-CoV-2 sequences (SARS-CoV-2-MSA-2). Sequence intervals are relative
to the reference genome NC_045512.2.

17

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

Name

Sequence
interval

Sequence

Secondary structure

SARS-CoV-2conservedstructured-1
SARS-CoV-2conservedstructured-2
SARS-CoV-2conservedstructured-3
SARS-CoV-2conservedstructured-4
SARS-CoV-2conservedstructured-5
SARS-CoV-2conservedstructured-6
SARS-CoV-2conservedstructured-7
SARS-CoV-2conservedstructured-8
SARS-CoV-2conservedstructured-9
SARS-CoV-2conservedstructured-10
SARS-CoV-2conservedstructured-11
SARS-CoV-2conservedstructured-12
SARS-CoV-2conservedstructured-13
SARS-CoV-2conservedstructured-14
SARS-CoV-2conservedstructured-15
SARS-CoV-2conservedstructured-16
SARS-CoV-2conservedstructured-17
SARS-CoV-2conservedstructured-18
SARS-CoV-2conservedstructured-19
SARS-CoV-2conservedstructured-20
SARS-CoV-2conservedstructured-21
SARS-CoV-2conservedstructured-22
SARS-CoV-2conservedstructured-23
SARS-CoV-2conservedstructured-24
SARS-CoV-2conservedstructured-25
SARS-CoV-2conservedstructured-26
SARS-CoV-2conservedstructured-27
SARS-CoV-2conservedstructured-28
SARS-CoV-2conservedstructured-29

918-1037

ACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCC
GUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCU
GAAAAGAGCUAUGAAUUGCAGACACCUUUUGAAAUUAA
AUGUUGACACUGACUUAACAAAGCCUUACAUUAAGUGGGAU
UUGUUAAAAUAUGACUUCACGGAAGAGAGGUUAAAACUCUU
UGACCGUUAUUUUAAAUAUUGGGAUCAGACAUACCACC
UCUACUACCCUUCUGCUCGCAUAGUGUAUACAGCUUGCUCU
CAUGCCGCUGUUGAUGCACUAUGUGAGAAGGCAUUAAAAUA
UUUGCCUAUAGAUAAAUGUAGUAGAAUUAUACCUGCAC
UUUAGGUGUUUUAAUGUCUAAUUUAGGCAUGCCUUCUUACU
GUACUGGUUACAGAGAAGGCUAUUUGAACUCUACUAAUGUC
ACUAUUGCAACCUACUGUACUGGUUCUAUACCUUGUAG
AAUCGACGGUUCAUCCGGAGUUGUUAAUCCAGUAAUGGAAC
CAAUUUAUGAUGAACCGACGACGACUACUAGCGUGCCUUUG
UAAGCACAAGCUGAUGAGUACGAACUUAUGUACUCAUU
CCAAUUUAUGAUGAACCGACGACGACUACUAGCGUGCCUUU
GUAAGCACAAGCUGAUGAGUACGAACUUAUGUACUCAUUCG
UUUCGGAAGAGACAGGUACGUUAAUAGUUAAUAGCGUA
AUGCAACUAAUAAAGCCACGUAUAAACCAAAUACCUGGUGUA
UACGUUGUCUUUGGAGCACAAAACCAGUUGAAACAUCAAAU
UCGUUUGAUGUACUGAAGUCAGAGGACGCGCAGGGAA
UUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAA
AUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUC
ACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACA
AGUUUUUCUGUUUGGAACUUUAAUUUUAGCCAUGGCAGAUU
CCAACGGUACUAUUACCGUUGAAGAGCUUAAAAAGCUCCUU
GAACAAUGGAACCUAGUAAUAGGUUUCCUAUUCCU
CAUUACUUCAGGUGAUGGCACAACAAGUCCUAUUUCUGAAC
AUGACUACCAGAUUGGUGGUUAUACUGAAAAAUGGGAAUCU
GGAGUAAAAGACUGUGUUGUAUUACACAGUUACUUCAC
AUUAAAUCACACUAAAAAGUGGAAAUACCCACAAGUUAAUGG
UUUAACUUCUAUUAAAUGGGCAGAUAACAACUGUUAUCUUG
CCACUGCAUUGUUAACACUCCAACAAAUAGAGUUGAA
UGUAAGCACAAGCUGAUGAGUACGAACUUAUGUACUCAUUC
GUUUCGGAAGAGACAGGUACGUUAAUAGUUAAUAGCGUACU
UCUUUUUCUUGCUUUCGUGGUAUUCUUGCUAGUUACAC
GCUAAAUUGUUACAUAAACCUAUUGUUUGGCAUGUUAACAA
UGCAACUAAUAAAGCCACGUAUAAACCAAAUACCUGGUGUA
UACGUUGUCUUUGGAGCACAAAACCAGUUGAAACAUCA
UUAUUGUAAAUCACAUAAACCACCCAUUAGUUUUCCAUUGU
GUGCUAAUGGACAAGUUUUUGGUUUAUAUAAAAAUACAUGU
GUUGGUAGCGAUAAUGUUACUGACUUUAAUGCAAUUGC
UGUACUGGUUACAGAGAAGGCUAUUUGAACUCUACUAAUGU
CACUAUUGCAACCUACUGUACUGGUUCUAUACCUUGUAGUG
UUUGUCUUAGUGGUUUAGAUUCUUUAGACACCUAUCCU
GGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACG
GUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGU
UUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUG
UUACCAGAUCCAUCAAAACCAAGCAAGAGGUCAUUUAUUGA
AGAUCUACUUUUCAACAAAGUGACACUUGCAGAUGCUGGCU
UCAUCAAACAAUAUGGUGAUUGCCUUGGUGAUAUUGCU
ACUAUUGUAUACCUUACAAUAGUGUAACUUCUUCAAUUGUC
AUUACUUCAGGUGAUGGCACAACAAGUCCUAUUUCUGAACA
UGACUACCAGAUUGGUGGUUAUACUGAAAAAUGGGAAU
GGGCAUUGAUUUAGAUGAGUGGAGUAUGGCUACAUACUACU
UAUUUGAUGAGUCUGGUGAGUUUAAAUUGGCUUCACAUAUG
UAUUGUUCUUUCUACCCUCCAGAUGAGGAUGAAGAAGA
UAAGGAAGGAAGUUCUGUUGAAUUAAAACACUUCUUCUUUG
CUCAGGAUGGUAAUGCUGCUAUCAGCGAUUAUGACUACUAU
CGUUAUAAUCUACCAACAAUGUGUGAUAUCAGACAACU
CAAUAUUGUUAACGUGAGUCUUGUAAAACCUUCUUUUUACG
UUUACUCUCGUGUUAAAAAUCUGAAUUCUUCUAGAGUUCCU
GAUCUUCUGGUCUAAACGAACUAAAUAUUAUAUU
AAUUCAGUUGUCUUCCUAUUCUUUAUUUGACAUGAGUAAAU
UUCCCCUUAAAUUAAGGGGUACUGCUGUUAUGUCUUUAAAA
GAAGGUCAAAUCAAUGAUAUGAUUUUAUCUCUUCUUAG
GAAGAGAAGUUUAAGGAAGGUGUAGAGUUUCUUAGAGACGG
UUGGGAAAUUGUUAAAUUUAUCUCAACCUGUGCUUGUGAAA
UUGUCGGUGGACAAAUUGUCACCUGUGCAAAGGAAAUU
AAAAAGGCUGGUGGCACUACUGAAAUGCUAGCGAAAGCUUU
GAGAAAAGUGCCAACAGACAAUUAUAUAACCACUUACCCGG
GUCAGGGUUUAAAUGGUUACACUGUAGAGGAGGCAAAG
GAUUCCAACGGUACUAUUACCGUUGAAGAGCUUAAAAAGCU
CCUUGAACAAUGGAACCUAGUAAUAGGUUUCCUAUUCCUUA
CAUGGAUUUGUCUUCUACAAUUUGCCUAUGCCAACAGG
CGUUUCGGAAGAGACAGGUACGUUAAUAGUUAAUAGCGUAC
UUCUUUUUCUUGCUUUCGUGGUAUUCUUGCUAGUUACACUA
GCCAUCCUUACUGCGCUUCGAUUGUGUGCGUACUGCUG
AUCUAGUACAACAGGAGUCACCUUUUGUUAUGAUGUCAGCA
CCACCUGCUCAGUAUGAACUUAAGCAUGGUACAUUUACUUG
UGCUAGUGAGUACACUGGUAAUUACCAGUGUGGUCACU
UGUUUGUCUUAGUGGUUUAGAUUCUUUAGACACCUAUCCUU
CUUUAGAAACUAUACAAAUUACCAUUUCAUCUUUUAAAUGG
GAUUUAACUGCUUUUGGCUUAGUUGCAGAGUGGUUUUU
AAAGUGCAGUGAAAAGAACAAUCAAGGGUACACACCACUGG
UUGUUACUCACAAUUUUGACUUCACUUUUAGUUUUAGUCCA
GAGUACUCAAUGGUCUUUGUUCUUUUUUUUGUAUGAAA

.....................(((((((((...((((..((((
(.((.((((((......)))))))).)))))...(((((...
.)))))........)))))))))))))........
(((((((..(..(.((((((((..(((((.....))))).)
)))))))...........((((.((((((.......))))))
..))))...........)..)..))).))))......
((((((((...(((((((((((((((((((((((..((..
....)).)))))..)))))))))))))).(((((........
..))))).)))).....)))))))).............
..(((((((..(((((((((...)))))))(((((((..((
(((.....)))))))))))).......................)
)..)).)))))...(((.(((.....)))..))).
..(((.(((((((((..((((((....((((....))))..)
)))))..))))))))).))).......((((((((.......
.))))..))))(((((((((......))))))))).
..................(((..(((((.((((((((((....
.(((....)))((((((((((......)))))))))).(((
((....))))))))))))))).))))).....))).
.(((......((((((.(((((((.((((......)))).))
))))).).)))))..((.......((((....((((((((..
..))))))))))))..(((....)))))))).....
....(((((.....))))).........(((((..........(
((((((..((.((((.(((.....))).))))))..)))))
))..((((((.....))))))...)))))....
.((((.(((((((((..((........))))).))))))...
((((((((....))))))))..(((((.....)))))...)
)))...((((((((....))))))))........
..(((((((((((..((......))..((((((((.(.(..(
((((((((.....)))))))))..).).)))))))))))))
))))))..((((((((......)))))))).......
.........((.(((...((((......))))...))).)).(
((((((.(((((.....((((((((((....)))))).)))
).......((((........))))))))))))))))
((((((((.((((.((((((((((......)))))))))).
)))).((((((((..(((((((((........)))))))))
)))))))).))).....(((((....))))).))))).
(((..((((((((((...((........)).))).)))))))
........((((((.(((((((.((((......)))).))))
))).).))))).))).....................
....(((((((((...((((...((((((((............
))))))))....)))).)))))))))........(((..((.
.(((((......)))))..))....))).......
(((.(((....))).(((((..((((((((...((....))(
((((..(((((((((......(((.....)))..)))).).)
)))..))))))))))))))))))..)))........
.....((((...(((.((((((((.....((((((.(((((.
.....)))))..)))))).........(((((((.((......
)))))))))(((....)))))))))))))).))))
(((((((...............(((((..(((((((.(((((
((.....)))))))..))))))).))))).......(((.((
((((.......))))))..)))))))))).......
(((((((((.....)))))))))..............(((((
((((.....))))))))).......((((((((.(.(..(((
((((((.....)))))))))..).).))))))))..
..((((((..((((((((((..((((((....)))))))))
)))))))((((.(..((........))..).)))))).))))
....((((((....((((.....))))..))))))..
..((.(((((((...((((.......))))...))))))).)
).....(((((..((((....))))(((((((((.......)
)))))))))))))....(((.((....)).)))...
.((((((....(((.((((..(((((((......))))))).
..)))).)))(((........((((((.....))))))..((
((....))))..)))......)))))).....
..................((((((....((((((((((.....(
((((((...)))))))...))))..))))))....))))))
(((.((((((......)))))).))).........
........((((.((((((.(....).))))))..))))(((
(((((((((....))))..))))))))((..(..((((..(
((((....)))))....))))..)..)).........
.....(.(((.(((((((.((.((.....(((....))))).
))...))))))).))).)..(((((((((((...((((...
...)))).....))))))...)))))...........
.....((((((((....))))))))..(((((.....)))))
((((......((((((((....))))))))..........((
(((..((((.....))))....)).)))....))))
.(((((....))))).(((((((..((((((...((((((.
..........((((.....)))).....(((((.....)))))
.........))))))..))))))..)))))))....
...((((((((((((((....))))))))..(((((....(
(((..((((.(((....)))..))))))))))))).....)
)))))((((.(((((((((....))))))))).)))).
.((((((..((((.(((((((...)))))))..(((......
..)))..)))).))))))..((((((........))))))..
...(((..(((...((......)).)))..)))...
...((((((.(((((((((((.((..(((....)))..))(
(((.(((((...(((..((((........))))..)))...)
))))..)))).....))))))))))).))))))....

14206-14325
17125-17244
7011-7130
26135-26254
26175-26294
6251-6370
40-157
26491-26607
25895-26014
5211-5330
26215-26334
6211-6330
16445-16564
7051-7170
158-277
23977-24096
25855-25974
2943-3062
14726-14845
26375-26490
21365-21484
2158-2277
4174-4293
26528-26647
26255-26374
5651-5770
7131-7250
10970-11089

zscore

P
value

-4.38

0.999

-1.99

0.999

-6.85

0.999

-1.36

0.999

-5.44

0.999

-4.44

0.999

-2.52

0.999

-2.91

0.998

-3.52

0.998

-4.4

0.998

-2.76

0.998

-3.49

0.998

-1.03

0.998

-1.17

0.997

0.99

0.996

-2.87

0.996

-2.82

0.994

-4.25

0.994

-0.32

0.994

-3.02

0.994

-2.73

0.994

-2.27

0.994

-1.62

0.993

-1.33

0.993

-3.29

0.993

-2.31

0.992

-2.77

0.992

-0.12

0.992

-1.44

0.992

18

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

SARS-CoV-2conservedstructured-30
SARS-CoV-2conservedstructured-31
SARS-CoV-2conservedstructured-32
SARS-CoV-2conservedstructured-33
SARS-CoV-2conservedstructured-34
SARS-CoV-2conservedstructured-35
SARS-CoV-2conservedstructured-36
SARS-CoV-2conservedstructured-37
SARS-CoV-2conservedstructured-38
SARS-CoV-2conservedstructured-39
SARS-CoV-2conservedstructured-40
SARS-CoV-2conservedstructured-41
SARS-CoV-2conservedstructured-42
SARS-CoV-2conservedstructured-43
SARS-CoV-2conservedstructured-44
SARS-CoV-2conservedstructured-45
SARS-CoV-2conservedstructured-46
SARS-CoV-2conservedstructured-47
SARS-CoV-2conservedstructured-48
SARS-CoV-2conservedstructured-49
SARS-CoV-2conservedstructured-50
SARS-CoV-2conservedstructured-51
SARS-CoV-2conservedstructured-52
SARS-CoV-2conservedstructured-53
SARS-CoV-2conservedstructured-54
SARS-CoV-2conservedstructured-55
SARS-CoV-2conservedstructured-56
SARS-CoV-2conservedstructured-57
SARS-CoV-2conservedstructured-58
SARS-CoV-2conservedstructured-59

28838-28957
26095-26214
2903-3022
29550-29669
80-197
13886-14005
120-237
23697-23816
25655-25774
15606-15724
14526-14645
3808-3897
25935-26054
15645-15764
2518-2625
26568-26687
1238-1357
6451-6570
29078-29197
23497-23616
13686-13805
12610-12729
19645-19764
11050-11169
17445-17564
24256-24375
17525-17644
27248-27367
4574-4693
21325-21444

GUAGUCGCAACAGUUCAAGAAAUUCAACUCCAGGCAGCAGU
AGGGGAACUUCUCCUGCUAGAAUGGCUGGCAAUGGCGGUG
AUGCUGCUCUUGCUUUGCUGCUGCUUGACAGAUUGAACC
AAAUUGUUGAUGAGCCUGAAGAACAUGUCCAAAUUCACACA
AUCGACGGUUCAUCCGGAGUUGUUAAUCCAGUAAUGGAACC
AAUUUAUGAUGAACCGACGACGACUACUAGCGUGCCUU
UAAAAACUUUGCAACCAGUAUCUGAAUUACUUACACCACUG
GGCAUUGAUUUAGAUGAGUGGAGUAUGGCUACAUACUACUU
AUUUGAUGAGUCUGGUGAGUUUAAAUUGGCUUCACAUA
AAGGCAGAUGGGCUAUAUAAACGUUUUCGCUUUUCCGUUUA
CGAUAUAUAGUCUACUCUUGUGCAGAAUGAAUUCUCGUAAC
UACAUAGCACAAGUAGAUGUAGUUAACUUUAAUCUCAC
AAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACU
CACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGA
CACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACG
CAAUUGUUGUGAUGAUGAUUAUUUCAAUAAAAAGGACUGGU
AUGAUUUUGUAGAAAACCCAGAUAUAUUACGCGUAUACGCC
AACUUAGGUGAACGUGUACGCCAAGCUUUGUUAAAAAC
CACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGA
CACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUU
UCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGU
UGCCAUACCCACAAAUUUUACUAUUAGUGUUACCACAGAAA
UUCUACCAGUGUCUAUGACCAAGACAUCAGUAGAUUGUACA
AUGUACAUUUGUGGUGAUUCAACUGAAUGCAGCAAUCU
AACAGUUUACUCACACCUUUUGCUCGUUGCUGCUGGCCUU
GAAGCCCCUUUUCUCUAUCUUUAUGCUUUAGUCUACUUCUU
GCAGAGUAUAAACUUUGUAAGAAUAAUAAUGAGGCUUUG
UUACAACACAGACUUUAUGAGUGUCUCUAUAGAAAUAGAGA
UGUUGACACAGACUUUGUGAAUGAGUUUUACGCAUAUUUGC
GUAAACAUUUCUCAAUGAUGAUACUCUCUGACGAUGC
AGCUCUAGACUUAGUUUUAAGGAAUUACUUGUGUAUGCUGC
UGACCCUGCUAUGCACGCUGCUUCUGGUAAUCUAUUACUAG
AUAAACGCACUACGUGCUUUUCAGUAGCUGCACUUACU
CUCUAUGACAAACUUGUUUCAAGCUUUUUGGAAAUGAAGAG
UGAAAAGCAAGUUGAACAAAAGAUCGCUGAGAUUCCUAAAG
AGGAAGUU
CAUGACUACCAGAUUGGUGGUUAUACUGAAAAAUGGGAAUC
UGGAGUAAAAGACUGUGUUGUAUUACACAGUUACUUCACUU
CAGACUAUUACCAGCUGUACUCAACUCAAUUGAGUACA
GAUGUUGACACAGACUUUGUGAAUGAGUUUUACGCAUAUUU
GCGUAAACAUUUCUCAAUGAUGAUACUCUCUGACGAUGCUG
UUGUGUGUUUCAAUAGCACUUAUGCAUCUCAAGGUCUA
UUAACAGAGGAAGUUGUCUUGAAAACUGGUGAUUUACAACC
AUUAGAACAACCUACUAGUGAAGCUGUUGAAGCUCCAUUGG
UUGGUACACCAGUUUGUAUUAACGGG
UCCUUGAACAAUGGAACCUAGUAAUAGGUUUCCUAUUCCUU
ACAUGGAUUUGUCUUCUACAAUUUGCCUAUGCCAACAGGAA
UAGGUUUUUGUAUAUAAUUAAGUUAAUUUUCCUCUGGC
AUUGUGGUGAAACUUCAUGGCAGACGGGCGAUUUUGUUAAA
GCCACUUGCGAAUUUUGUGGCACUGAGAAUUUGACUAAAGA
AGGUGCCACUACUUGUGGUUACUUACCCCAAAAUGCUG
GAGUGUAAUGUGAAAACUACCGAAGUUGUAGGAGACAUUAU
ACUUAAACCAGCAAAUAAUAGUUUAAAAAUUACAGAAGAGGU
UGGCCACACAGAUCUAAUGGCUGCUUAUGUAGACAAU
AUGUAACACAAGCUUUCGGCAGACGUGGUCCAGAACAAACC
CAAGGAAAUUUUGGGGACCAGGAACUAAUCAGACAAGGAAC
UGAUUACAAACAUUGGCCGCAAAUUGCACAAUUUGCCC
CGUGCAGGCUGUUUAAUAGGGGCUGAACAUGUCAACAACUC
AUAUGAGUGUGACAUACCCAUUGGUGCAGGUAUAUGCGCUA
GUUAUCAGACUCAGACUAAUUCUCCUCGGCGGGCACGU
GAAGAAACAAUUUAUAAUUUACUUAAGGAUUGUCCAGCUGU
UGCUAAACAUGACUUCUUUAAGUUUAGAAUAGACGGUGACA
UGGUACCACAUAUAUCACGUCAACGUCUUACUAAAUAC
AUGGACAAUUCACCUAAUUUAGCAUGGCCUCUUAUUGUAAC
AGCUUUAAGGGCCAAUUCUGCUGUCAAAUUACAGAAUAAUG
AGCUUAGUCCUGUUGCACUACGACAGAUGUCUUGUGCU
UUGUAAAUAAGGGACACUUUGAUGGACAACAGGGUGAAGUA
CCAGUUUCUAUCAUUAAUAACACUGUUUACACAAAAGUUGA
UGGUGUUGAUGUAGAAUUGUUUGAAAAUAAAACAACAU
CAGAGUACUCAAUGGUCUUUGUUCUUUUUUUUGUAUGAAAA
UGCCUUUUUACCUUUUGCUAUGGGUAUUAUUGCUAUGUCU
GCUUUUGCAAUGAUGUUUGUCAAACAUAAGCAUGCAUUU
CAAUUACCUGCACCACGCACAUUGCUAACUAAGGGCACACU
AGAACCAGAAUAUUUCAAUUCAGUGUGUAGACUUAUGAAAA
CUAUAGGUCCAGACAUGUUCCUCGGAACUUGUCGGCGU
GCUAUGCAAAUGGCUUAUAGGUUUAAUGGUAUUGGAGUUAC
ACAGAAUGUUCUCUAUGAGAACCAAAAAUUGAUUGCCAACC
AAUUUAAUAGUGCUAUUGGCAAAAUUCAAGACUCACUU
AACUAUAGGUCCAGACAUGUUCCUCGGAACUUGUCGGCGUU
GUCCUGCUGAAAUUGUUGACACUGUGAGUGCUUUGGUUUA
UGAUAAUAAGCUUAAAGCACAUAAAGACAAAUCAGCUCA
AAUUAUUAUGAGGACUUUUAAAGUUUCCAUUUGGAAUCUUG
AUUACAUCAUAAACCUCAUAAUUAAAAAUUUAUCUAAGUCAC
UAACUGAGAAUAAAUAUUCUCAAUUAGAUGAAGAGCA
CACUUAACGAUCUAAAUGAAACUCUUGUUACAAUGCCACUU
GGCUAUGUAACACAUGGCUUAAAUUUGGAAGAAGCUGCUCG
GUAUAUGAGAUCUCUCAAAGUGCCAGCUACAGUUUCUG
UCAUGCAUGCAAAUUACAUAUUUUGGAGGAAUACAAAUCCA
AUUCAGUUGUCUUCCUAUUCUUUAUUUGACAUGAGUAAAUU
UCCCCUUAAAUUAAGGGGUACUGCUGUUAUGUCUUUAA

.(((((.....((((.((....)).)))).(((((((((((
(((((.....)))))))).....(((.(((((.(((((....
.))))).)))))..)))))))))))...)))))....
.....((((.((..(.((.....)).)..))...........((
(.(((((((((..((((((....((((....))))..))))
))..))))))))).)))))))..............
..............((((((.......)))(((.(((((..((
(.((...((((((((((..((((((....))))))))))))
)))).)))))..))).)).)))..))).........
.(((.((.(((((((((((..(((...((......))...))
).))))))))))))))))(((.(((.((((......(((((
((((.((....))..)))))))))..)))).))))))
...(((((((..((.((((.(((.....))).))))))..))
)))))..((((((.....))))))..((.(((..(((((.(
((((...))))).....)))))..))).)).....
...((((((.(((((...))))).))))))((((..((((.
.................)))).........(((((((((...((
....))...)))))))))....)))).........
...((((((..((((.....)))))))))).((((((((((
.(((((...))))).....)))))..((((((.(((((....
..)))))..)))))).....)))))..........
.......................((((((((((((((((...(
((((..((((((.......))))))..))))).(((((...)
)))))))))))))))...)))))............
..((((...............((.....)).))))((((((((
((...................))))).......((((((((((
((....)))))))))))).......)))))....
........((((......(((((((..(((.((....((((((
((..(((((...))))).........((((((....))))))
)))))))))).)))..))))))))))).......
...........((((((....))))))...(((((.((((((
((.........(((((.(((.((((((((....)))))))).
....)))...)))))...))))))))))))).....
(((..(((..(((((((((...(((((((......))))))
)...)))))))))..........)))..))).(((((....)
))))...
.(((((((((.....))))))))).(((...(((((...((
((((((((..((((((((......))))))))..)).))))
)))))))))..)))..((((((((.....)))))))).
(((.((((..((((..(..(.(.((((.((((((((....)
))))))).....)))).).)..).....))))..(((((...
((.(((((.....))))).)).))))))))).)))..
............((((......(((((((((.((((.......
))))...(((.(((((((.((((.....)))).))))))).
))).)))))))))....))))...
..(((((((((.((((((((....))))))))....(((..
....))).))))....(((((...((((((.((....)).))
))))..))))).....)))))................
.((((.((((....)))).))))...(((.((((((.....(
((((...........)))))....................((((
(((((.....)))).)))))....))))))))).
(((((((((((.....((((.......))))...))))))))
))).........................(((((....((((.((
(((...........))))))))).))))).....
.................(((...(.((((((.(......)((((
(.....))))))))))).)...(((((((........)))))
)).........)))(((((((....)))))))..
(((((..((((.......(((.((((..((((((...((((.
...)))).))))))....(((((((((......))))))))
)..)))).)))(((.....)))...))))..))))).
....................(((((((((.(((..(((....))
)..))).....)))))))))((((...(((((.((((.(((
((.......))))).)))).)))))..))))....
..((((((((((............(((((.((((..((....)
)..)))))))))((((((.((......))))))))..))))
.)).))))....((((...(((....)))..)))).
...(((((((...(((...(((((((.(((.((........)
).))))))))))....((((((((((.((......)).)))
))))))).)))....)))))))...............
(((((.(((....))))))))..........((((((.....
((..(..(((((........)))))..)..))(((((.(((.
...))).((((....)))).)))))..))))))...
.........((.((((((((..((((.......))))......
.....((((......)))).)))))).((((((((.....))
))))))..((((.((((....)))).)))))).))
(((((....)))))....................(((((.....
....((((((...))))))......(((((((((((...(((
....)))....)))))))...)))))))))....
......(((.((.((((.((((....)))).)))))).....
.)))(((((..(((((.......((.((((((((((((((.
...)))))).)))))))).))..))))).)))))...
....(((((((((.......(((.((((....)))).)))((
(...))).....)))))))))...........((...((((((
(.(((((((....))))))).)))).)))..))..
..........(((((((..((..(.(((((((..(((....))
)..)))))))...)..))..)))))))((((((((((.(((
((.((((....))))..))))))))...))))))).
.(((((((((((((.....((...((((((..((........
....))..)))))).)).....))))).))))((((.....(
((((((...)))))))...))))..)))).......

-2.64

0.992

-1.91

0.992

-0.97

0.991

-1.83

0.990

-0.8

0.990

-0.37

0.989

-2.33

0.989

-2.64

0.989

-1.15

0.989

-1.81

0.988

-1.64

0.986

-1.32

0.983

-4.97

0.983

-2.07

0.983

-1.93

0.982

-2.13

0.982

-0.75

0.981

-0.83

0.981

-1.24

0.980

-2.42

0.979

-3.1

0.978

-1.94

0.978

-0.89

0.977

-0.33

0.977

-2.14

0.974

-0.32

0.974

-2.22

0.973

-3.72

0.972

-3.73

0.971

-1.24

0.970

19

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

SARS-CoV-2conservedstructured-60
SARS-CoV-2conservedstructured-61
SARS-CoV-2conservedstructured-62
SARS-CoV-2conservedstructured-63
SARS-CoV-2conservedstructured-64
SARS-CoV-2conservedstructured-65
SARS-CoV-2conservedstructured-66
SARS-CoV-2conservedstructured-67
SARS-CoV-2conservedstructured-68
SARS-CoV-2conservedstructured-69
SARS-CoV-2conservedstructured-70
SARS-CoV-2conservedstructured-71
SARS-CoV-2conservedstructured-72
SARS-CoV-2conservedstructured-73
SARS-CoV-2conservedstructured-74
SARS-CoV-2conservedstructured-75
SARS-CoV-2conservedstructured-76
SARS-CoV-2conservedstructured-77
SARS-CoV-2conservedstructured-78
SARS-CoV-2conservedstructured-79
SARS-CoV-2conservedstructured-80
SARS-CoV-2conservedstructured-81
SARS-CoV-2conservedstructured-82
SARS-CoV-2conservedstructured-83
SARS-CoV-2conservedstructured-84
SARS-CoV-2conservedstructured-85
SARS-CoV-2conservedstructured-86
SARS-CoV-2conservedstructured-87
SARS-CoV-2conservedstructured-88
SARS-CoV-2conservedstructured-89

7771-7890
19765-19884
6971-7090
28998-29117
5011-5130
4094-4213
1598-1717
11090-11209
17965-18084
25815-25934
14446-14565
2118-2237
17205-17324
7171-7290
14766-14885
11730-11849
29238-29357
1558-1677
4214-4333
9410-9529
13806-13925
23537-23656
9210-9329
6091-6210
29118-29237
28958-29077
29278-29397
14046-14165
9250-9369
26415-26527

CUUUACUUUGAUAAAGCUGGUCAAAAGACUUAUGAAAGACA
UUCUCUCUCUCAUUUUGUUAACUUAGACAACCUGAGAGCUA
AUAACACUAAAGGUUCAUUGCCUAUUAAUGUUAUAGUU
UACCUGUUAAUGUAGCAUUUGAGCUUUGGGCUAAGCGCAAC
AUUAAACCAGUACCAGAGGUGAAAAUACUCAAUAAUUUGGG
UGUGGACAUUGCUGCUAAUACUGUGAUCUGGGACUACA
UAAGUGUUUGCCUAGGUUCUUUAAUCUACUCAACCGCUGCU
UUAGGUGUUUUAAUGUCUAAUUUAGGCAUGCCUUCUUACUG
UACUGGUUACAGAGAAGGCUAUUUGAACUCUACUAAUG
AGGCCAAACUGUCACUAAGAAAUCUGCUGCUGAGGCUUCUA
AGAAGCCUCGGCAAAAACGUACUGCCACUAAAGCAUACAAU
GUAACACAAGCUUUCGGCAGACGUGGUCCAGAACAAAC
GUUGUGGACAUGUCAAUGACAUAUGGACAACAGUUUGGUCC
AACUUAUUUGGAUGGAGCUGAUGUUACUAAAAUAAAACCUC
AUAAUUCACAUGAAGGUAAAACAUUUUAUGUUUUACCU
CUUUCUUAAAGAAAGAUGCUCCAUAUAUAGUGGGUGAUGUU
GUUCAAGAGGGUGUUUUAACUGCUGUGGUUAUACCUACUAA
AAAGGCUGGUGGCACUACUGAAAUGCUAGCGAAAGCUU
GUCUUAAUGACAACCUUCUUGAAAUACUCCAAAAAGAGAAAG
UCAACAUCAAUAUUGUUGGUGACUUUAAACUUAAUGAAGAG
AUCGCCAUUAUUUUGGCAUCUUUUUCUGCUUCCACAA
AUGCCUUUUUACCUUUUGCUAUGGGUAUUAUUGCUAUGUCU
GCUUUUGCAAUGAUGUUUGUCAAACAUAAGCAUGCAUUUCU
CUGUUUGUUUUUGUUACCUUCUCUUGCCACUGUAGCUU
CUGAUAGAGACCUUUAUGACAAGUUGCAAUUUACAAGUCUU
GAAAUUCCACGUAGGAAUGUGGCAACUUUACAAGCUGAAAA
UGUAACAGGACUCUUUAAAGAUUGUAGUAAGGUAAUCA
GAUGCCAACUAUUUUCUUUGCUGGCAUACUAAUUGUUACGA
CUAUUGUAUACCUUACAAUAGUGUAACUUCUUCAAUUGUCA
UUACUUCAGGUGAUGGCACAACAAGUCCUAUUUCUGAA
AUGGUGUUCCAUUUGUAGUUUCAACUGGAUACCACUUCAGA
GAGCUAGGUGUUGUACAUAAUCAGGAUGUAAACUUACAUAG
CUCUAGACUUAGUUUUAAGGAAUUACUUGUGUAUGCUG
CACUGUUUAUGAAAAACUCAAACCCGUCCUUGAUUGGCUUG
AAGAGAAGUUUAAGGAAGGUGUAGAGUUUCUUAGAGACGGU
UGGGAAAUUGUUAAAUUUAUCUCAACCUGUGCUUGUGA
UAUUUGCCUAUAGAUAAAUGUAGUAGAAUUAUACCUGCACG
UGCUCGUGUAGAGUGUUUUGAUAAAUUCAAAGUGAAUUCAA
CAUUAGAACAGUAUGUCUUUUGUACUGUAAAUGCAUUG
UCUUUAGAAACUAUACAAAUUACCAUUUCAUCUUUUAAAUGG
GAUUUAACUGCUUUUGGCUUAGUUGCAGAGUGGUUUUUGG
CAUAUAUUCUUUUCACUAGGUUUUUCUAUGUACUUGGA
GCUCAGGAUGGUAAUGCUGCUAUCAGCGAUUAUGACUACUA
UCGUUAUAAUCUACCAACAAUGUGUGAUAUCAGACAACUAC
UAUUUGUAGUUGAAGUUGUUGAUAAGUACUUUGAUUGU
UAUGAAUUCACAGGGACUACUCCCACCCAAGAAUAGCAUAG
AUGCCUUCAAACUCAACAUUAAAUUGUUGGGUGUUGGUGGC
AAACCUUGUAUCAAAGUAGCCACUGUACAGUCUAAAAU
GGAAGUCACACCUUCGGGAACGUGGUUGACCUACACAGGU
GCCAUCAAAUUGGAUGACAAAGAUCCAAAUUUCAAAGAUCAA
GUCAUUUUGCUGAAUAAGCAUAUUGACGCAUACAAAAC
GGUUGUAACCAUACAGGUGUUGUUGGAGAAGGUUCCGAAG
GUCUUAAUGACAACCUUCUUGAAAUACUCCAAAAAGAGAAAG
UCAACAUCAAUAUUGUUGGUGACUUUAAACUUAAUGAA
UGAGAAAAGUGCCAACAGACAAUUAUAUAACCACUUACCCG
GGUCAGGGUUUAAAUGGUUACACUGUAGAGGAGGCAAAGAC
AGUGCUUAAAAAGUGUAAAAGUGCCUUUUACAUUCUAC
CUGGUGGUAUUGUAGCUAUCGUAGUAACAUGCCUUGCCUA
CUAUUUUAUGAGGUUUAGAAGAGCUUUUGGUGAAUACAGUC
AUGUAGUUGCCUUUAAUACUUUACUAUUCCUUAUGUCAU
ACAAUGGCAGACCUCGUCUAUGCUUUAAGGCAUUUUGAUGA
AGGUAAUUGUGACACAUUAAAAGAAAUACUUGUCACAUACAA
UUGUUGUGAUGAUGAUUAUUUCAAUAAAAAGGACUGG
CAUAUGAGUGUGACAUACCCAUUGGUGCAGGUAUAUGCGCU
AGUUAUCAGACUCAGACUAAUUCUCCUCGGCGGGCACGUAG
UGUAGCUAGUCAAUCCAUCAUUGCCUACACUAUGUCAC
GUACUGUAGGCACGGCACUUGUGAAAGAUCAGAAGCUGGU
GUUUGUGUAUCUACUAGUGGUAGAUGGGUACUUAACAAUGA
UUAUUACAGAUCUUUACCAGGAGUUUUCUGUGGUGUAGA
CAGUUAACUGGUUAUAAGAAACCUGCUUCAAGAGAGCUUAA
AGUUACAUUUUUCCCUGACUUAAAUGGUGAUGUGGUGGCUA
UUGAUUAUAAACACUACACACCCUCUUUUAAGAAAGGA
CCAAGGAAAUUUUGGGGACCAGGAACUAAUCAGACAAGGAA
CUGAUUACAAACAUUGGCCGCAAAUUGCACAAUUUGCCCCC
AGCGCUUCAGCGUUCUUCGGAAUGUCGCGCAUUGGCAU
AGCUUGAGAGCAAAAUGUCUGGUAAAGGCCAACAACAACAA
GGCCAAACUGUCACUAAGAAAUCUGCUGCUGAGGCUUCUAA
GAAGCCUCGGCAAAAACGUACUGCCACUAAAGCAUACA
GCCAUCAAAUUGGAUGACAAAGAUCCAAAUUUCAAAGAUCAA
GUCAUUUUGCUGAAUAAGCAUAUUGACGCAUACAAAACAUU
CCCACCAACAGAGCCUAAAAAGGACAAAAAGAAGAAG
GGUGUACUGACAUUAGAUAAUCAAGAUCUCAAUGGUAACUG
GUAUGAUUUCGGUGAUUUCAUACAAACCACGCCAGGUAGUG
GAGUUCCUGUUGUAGAUUCUUAUUAUUCAUUGUUAAUG
GUUUGUGUAUCUACUAGUGGUAGAUGGGUACUUAACAAUGA
UUAUUACAGAUCUUUACCAGGAGUUUUCUGUGGUGUAGAUG
CUGUAAAUUUACUUACUAAUAUGUUUACACCACUAAUU
GUUUACUCUCGUGUUAAAAAUCUGAAUUCUUCUAGAGUUCC
UGAUCUUCUGGUCUAAACGAACUAAAUAUUAUAUUAGUUUU
UCUGUUUGGAACUUUAAUUUUAGCCAUGGCA

.....((((.((((..((.......))..)))).)))).....
....((((((..(((((......)))))..))))))...(((
(((.(((((((.....)))).))).))))))....
..(((.(((((((.((.(((.(((.....)))))).)).))
))))).((((((.(((..(((...((((((((....)))))
)))...)))..)))....))))).)....)))......
..((((.(((..((((((....))))))..))).))))....
((((.((((..(((((((...)))))))(((((((..(((
((.....)))))))))))).....))))))))......
.((((......................((((((((((((...)
)))))))))))...((((.(((((...(((((..........
......))))).)))))))))))))..........
..((((((.(((((...)))))...((((.((((((.((((
((.....)))))).)))))).))))..................
..))))))...(((((((((((...)))))))))))
..(((((.((.((...(((.((((.....)))))))...)).
)).)))))(((((((((......(((((..((((..((....
.))..))))..))))))))))))))(((....))).
(((.....)))...((((((((....(((......)))((((
(((.((.((....)).)).)))))))....)))).))))((
((.((((......))))))))................
.................(((((((.(((((((((...(....)
....))))))))).......((((.(((((.(((......))
).))))).))))..............)))))))..
..(((....(((((....((((((((((.(((...((.((((
(((((((((((....)))))).)).))).)))))).))).)
))))).....(((....)))))))...))))).))).
.((((((.(..........).)))))).......(((((.(((
((((((.....)))))))))))))).........(((((((
((.....)))))))))....................
..(((((..(((..((((((((..(((((......)))))(
((((((.(((...(((((.......)))))....))).))))
)))..............))))))))..))).))))).
(((.((((.(((.((((((..(((..(((((((...((((.
.....))))))))))).)))...)))))).))).))))(((
(((((((((....))))..)))))))).......))).
((((((....))))))((((((((.(((((((((((((((
(....))))))).))))(((((.....)))))...))))).
))......((((((((.....))))))))...)))))).
...(((((((((((..(((((.((((((........)))))
))))))..((((..(((...)))..)))).)))))))))))
...............((((((..........)))))).
(((...(((((((....))))))))))(((((((((.....
..)))))))))...(((((((((.((....)).))((((((
.....))))))...))))))).................
...((....((((((.(((((......((((...........(
(((.((((((((((((......)))))))).)))).)))).
..))))......))))))).))))....))......
....((((.(((..((....)).)))))))........((((.
......((((((.......))))))..............((((.
..((((.....))))...)))))))).......
(((....))).....((.((..((.(((((((((......((
(.....)))))))))))).))..)).))...(((..(((((
((.((.((....)).)).)))))))...)))......
..((((.((((................((((((...((((...
...)))).....))))))))))(((((..(((((...(((.
(........).))).....)))))))))).))))..
..((((((((.((.((((...)))).)))))))..)))...
.....(((((((..(((.((((..((.((..(.((((....)
))).)..))...))..)))).)))..)))))))....
(((((.....((((((((.(((((....)))))...)))).
)))).)))))............((((((.(..((((((((..
..).)))).)))..).))))))...............
....(((((.(((.......(((((((((......)))))))
))..))).)))))..........((.....))(.((((((((
(((.((((.........)))).))))))))))))..
(((((.(((((((.(..(((.(((....))).))).).)))
))))..(((((((.....))))))))))))...........(
((((((((.((((....))))...)))))))))....
..((.((((((((......)))).((((.....))))....)
))))).......(((..((((((.((((.(((((((..(((
.....)))..)))))))))))....))))))..))).
((((........(((((.((((....(((((((........))
)))))......))))..(((((((....))))))))))))(
(((....((((((....)))))).)))).))))...
.((((.((.(((..((((..((((..((((...........)
)))...((.......)).....))))(((((((((((...))
)))))))))....))))..)))..)).)))).....
.........((((((.......)))))).((((.........(
(((...((((.....))))...))))..................
........((((....))).).....))))...
.......(((((.(..(((((.(((((((((((((.((((.
((((((..((...))..))))))...((((........))))
)))).)))))).))).)))))))))..).)))))...
(((...((((((((((....))).)))))))..)))......
....(((((.((((....))))...)))))(((((((((...
((((......))))......))))))))).......
........(((((((((((....((.....))(((((((((.
((((....)))).(((((((((((........)))))))...
.))))))))))))).)))))).)))))..

-1.93

0.967

-0.84

0.965

-1.9

0.963

-4.19

0.963

-4.19

0.963

0.4

0.958

-2

0.955

-1.63

0.955

-0.96

0.952

-4.17

0.952

-1.41

0.948

-2.75

0.948

-2.61

0.947

-0.53

0.945

-2.13

0.943

-1.59

0.942

-1.58

0.941

-1.18

0.941

-0.39

0.940

-1.74

0.940

-1.73

0.940

-0.51

0.940

-0.31

0.939

-2.57

0.939

-3.14

0.938

-2.78

0.935

-1.58

0.935

-2.05

0.935

-0.53

0.934

-1.94

0.934

20

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

SARS-CoV-2conservedstructured-90
SARS-CoV-2conservedstructured-91
SARS-CoV-2conservedstructured-92
SARS-CoV-2conservedstructured-93
SARS-CoV-2conservedstructured-94
SARS-CoV-2conservedstructured-95
SARS-CoV-2conservedstructured-96
SARS-CoV-2conservedstructured-97
SARS-CoV-2conservedstructured-98
SARS-CoV-2conservedstructured-99
SARS-CoV-2conservedstructured-100
SARS-CoV-2conservedstructured-101
SARS-CoV-2conservedstructured-102
SARS-CoV-2conservedstructured-103
SARS-CoV-2conservedstructured-104
SARS-CoV-2conservedstructured-105
SARS-CoV-2conservedstructured-106

14846-14965
4971-5090
9610-9729
5691-5810
25016-25135
6411-6530
26608-26727
11010-11129
10850-10969
14886-15005
25216-25335
11690-11809
5251-5370
1198-1317
28758-28877
17765-17884
22101-22218

ACUAUUUGUAGUUGAAGUUGUUGAUAAGUACUUUGAUUGUU
ACGAUGGUGGCUGUAUUAAUGCUAACCAAGUCAUCGUCAAC
AACCUAGACAAAUCAGCUGGUUUUCCAUUUAAUAAAUG
GGUGUUUACAACAGUAGACAACAUUAACCUCCACACGCAAG
UUGUGGACAUGUCAAUGACAUAUGGACAACAGUUUGGUCCA
ACUUAUUUGGAUGGAGCUGAUGUUACUAAAAUAAAACC
CUUACUAAUGAUGUUUCUUUUUUAGCACAUAUUCAGUGGAU
GGUUAUGUUCACACCUUUAGUACCUUUCUGGAUAACAAUUG
CUUAUAUCAUUUGUAUUUCCACAAAGCAUUUCUAUUGG
ACCACCUGCUCAGUAUGAACUUAAGCAUGGUACAUUUACUU
GUGCUAGUGAGUACACUGGUAAUUACCAGUGUGGUCACUAU
AAACAUAUAACUUCUAAAGAAACUUUGUAUUGCAUAGA
UAGAUAAAUAUUUUAAGAAUCAUACAUCACCAGAUGUUGAUU
UAGGUGACAUCUCUGGCAUUAAUGCUUCAGUUGUAAACAUU
CAAAAAGAAAUUGACCGCCUCAAUGAGGUUGCCAAGA
AGAAGUAGUGGAAAAUCCUACCAUACAGAAAGACGUUCUUG
AGUGUAAUGUGAAAACUACCGAAGUUGUAGGAGACAUUAUA
CUUAAACCAGCAAAUAAUAGUUUAAAAAUUACAGAAGA
UACAUGGAUUUGUCUUCUACAAUUUGCCUAUGCCAACAGGA
AUAGGUUUUUGUAUAUAAUUAAGUUAAUUUUCCUCUGGCUG
UUAUGGCCAGUAACUUUAGCUUGUUUUGUGCUUGCUGC
GUUGUUACUCACAAUUUUGACUUCACUUUUAGUUUUAGUCC
AGAGUACUCAAUGGUCUUUGUUCUUUUUUUUGUAUGAAAAU
GCCUUUUUACCUUUUGCUAUGGGUAUUAUUGCUAUGUC
CUUCAUUAAAAGAAUUACUGCAAAAUGGUAUGAAUGGACGU
ACCAUAUUGGGUAGUGCUUUAUUAGAAGAUGAAUUUACACC
UUUUGAUGUUGUUAGACAAUGCUCAGGUGUUACUUUCC
UACGAUGGUGGCUGUAUUAAUGCUAACCAAGUCAUCGUCAA
CAACCUAGACAAAUCAGCUGGUUUUCCAUUUAAUAAAUGGG
GUAAGGCUAGACUUUAUUAUGAUUCAAUGAGUUAUGAG
GGUUUUAUAGCUGGCUUGAUUGCCAUAGUAAUGGUGACAAU
UAUGCUUUGCUGUAUGACCAGUUGCUGUAGUUGUCUCAAG
GGCUGUUGUUCUUGUGGAUCCUGCUGCAAAUUUGAUGAA
GUGUUUAUGAUUACUUAGUUUCUACACAGGAGUUUAGAUAU
AUGAAUUCACAGGGACUACUCCCACCCAAGAAUAGCAUAGA
UGCCUUCAAACUCAACAUUAAAUUGUUGGGUGUUGGUG
GGUUUAACUUCUAUUAAAUGGGCAGAUAACAACUGUUAUCU
UGCCACUGCAUUGUUAACACUCCAACAAAUAGAGUUGAAGU
UUAAUCCACCUGCUCUACAAGAUGCUUAUUACAGAGCA
UGCAACCAAAUGUGCCUUUCAACUCUCAUGAAGUGUGAUCA
UUGUGGUGAAACUUCAUGGCAGACGGGCGAUUUUGUUAAA
GCCACUUGCGAAUUUUGUGGCACUGAGAAUUUGACUAAA
UCAAGGAACAACAUUGCCAAAAGGCUUCUACGCAGAAGGGA
GCAGAGGCGGCAGUCAAGCCUCUUCUCGUUCCUCAUCACG
UAGUCGCAACAGUUCAAGAAAUUCAACUCCAGGCAGCAG
CUUUAUUUCACCUUAUAAUUCACAGAAUGCUGUAGCCUCAA
AGAUUUUGGGACUACCAACUCAAACUGUUGAUUCAUCACAG
GGCUCAGAAUAUGACUAUGUCAUAUUCACUCAAACCAC
AGGAAAACAGGGUAAUUUCAAAAAUCUUAGGGAAUUUGUGU
UUAAGAAUAUUGAUGGUUAUUUUAAAAUAUAUUCUAAGCACA
CGCCUAUUAAUUUAGUGCGUGAUCUCCCUCAGGGU

..........((((((...((((((..((.((..(.(((((..
((((((((((...(((....)))...)))))))))))))))
)..))))..))))))(((....))))))))).....
(((((((((....))))))(((((...(((((((((....)
.)))))).(((((...)))))..))....((((((.(((((
(.....)))))).)))))))))))...........)))
.......(((.((((........))))))).....((((((..
....)))))).((..(((...((((.((((..((((.((...
....)).))))...)))).)))).....)))..))
...(((((((.(((....)))..)))).)))........(((
(((((((((.(((((((((....))))))))).)))))).
....((((((.(((....)))...)))))).)))))).
.((((...........((((((.(((((....))))))))))
).(....))))).(((((........((((((...........
......))))))..(((((...))))))))))...
....(((((((.....))................(((.(((((
((((((((.....((((.......))))...)))))))))))
))...)))................)))))......
..((..((.........(((((...((((((.((....)).))
))))..)))))......((((((((.......((((((....
.)))))).....)))))))).))..))........
..((.(((((...(((..((((........))))..)))...)
))))..))(((((................((((....))))..
...(((((........))))).....)))))...
((((....((((.((((((.(((.((((((((......)))
))))).))))))))).))))....))))..(((...(((((
(...(.(((((.....))))))..))))))....))).
...((((((((((...(((....)))...))))))))))...
............((((((....(((((((.....)))))))..
.)))).)).....(((((((((...))))))))).
((((.((((((.(((.((((((((((....))))...))))
)).)))..)))))).))))..((((.((((..(((((((((
((....))))))).)))).)))).))))..........
(((((((((....(((.............(((((((......)
))))))...((((....))))....))).....)))))))))
..((((((((((((......)))))))).))))..
((...((((((.(((.....((((((((((....)))))).
)))).(((..(((((........))))).)))))).)))))
)....))....(((((..((........))..))))).
......((((((((((...(((....((((((((.(.(((..
...))).).))))))))((((...(((............))).
.)))).....))).))))).....)))))......
.............(((((.....((..(((((.....((((((
(((((.(((......))).))))).)))))).....))))).
.))...((((.((....)).))))...)))))...
.....................((((....))))((((.....((
..((((.....)))).))...((((.((....))))))))))
..(((((((((...)))))))))...........
.......................((((((((((....(((((((
.((((((..................)))))))))))))((((
(((......))).))))....))))).)))))

-0.79

0.934

-3.72

0.932

-0.85

0.932

-3.18

0.931

-1.16

0.926

-1.1

0.922

-1.64

0.922

0.12

0.922

-2.67

0.920

-1.33

0.919

-3.78

0.916

-1.17

0.913

-2.28

0.912

-0.42

0.910

-3.57

0.910

-2.03

0.903

-1.7

0.900

Table 2: SARS-CoV-2-conserved-structured. RNAz windows as scored by the P-value (P>0.9)
that overlap with conserved intervals from SARS-CoV-2-MSA-2 (97% conservation cutoff) by at least
15 nucleotides. Sequence intervals are relative to the reference genome NC_045512.2.

21

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

Name

Sequence
interval

Average
unpaired
probability
0.891105

Minimum
unpaired
probability
0.763759

SARS-CoV-2-conserved-unstructured-1

29074-29087

SARS-CoV-2-conserved-unstructured-2

8078-8094

0.82497

0.752542

SARS-CoV-2-conserved-unstructured-3

1359-1374

0.836512

0.716868

SARS-CoV-2-conserved-unstructured-4

21626-21643

0.857235

0.713387

SARS-CoV-2-conserved-unstructured-5

1420-1436

0.796631

0.697304

SARS-CoV-2-conserved-unstructured-6

18471-18484

0.779821

0.695284

SARS-CoV-2-conserved-unstructured-7

11910-11923

0.766973

0.683262

SARS-CoV-2-conserved-unstructured-8

23960-23981

0.787037

0.677563

SARS-CoV-2-conserved-unstructured-9

13990-14003

0.796334

0.661868

SARS-CoV-2-conserved-unstructured-10

10009-10035

0.760204

0.656672

SARS-CoV-2-conserved-unstructured-11

23700-23718

0.822733

0.654787

SARS-CoV-2-conserved-unstructured-12

18918-18934

0.832132

0.654059

SARS-CoV-2-conserved-unstructured-13

27385-27402

0.809693

0.653733

SARS-CoV-2-conserved-unstructured-14

5773-5789

0.808284

0.65353

SARS-CoV-2-conserved-unstructured-15

23910-23932

0.837777

0.652669

SARS-CoV-2-conserved-unstructured-16

17762-17785

0.767426

0.650277

SARS-CoV-2-conserved-unstructured-17

25569-25582

0.825796

0.648774

SARS-CoV-2-conserved-unstructured-18

19569-19588

0.75387

0.648103

SARS-CoV-2-conserved-unstructured-19

22552-22565

0.773461

0.646815

SARS-CoV-2-conserved-unstructured-20

25417-25437

0.747166

0.639634

SARS-CoV-2-conserved-unstructured-21

12195-12210

0.745911

0.634404

SARS-CoV-2-conserved-unstructured-22

6757-6783

0.78979

0.633073

SARS-CoV-2-conserved-unstructured-23

15236-15257

0.747024

0.630481

SARS-CoV-2-conserved-unstructured-24

6225-6238

0.734349

0.628462

SARS-CoV-2-conserved-unstructured-25

9578-9598

0.825697

0.627812

SARS-CoV-2-conserved-unstructured-26

21649-21662

0.820527

0.626762

SARS-CoV-2-conserved-unstructured-27

23985-23998

0.799754

0.625346

SARS-CoV-2-conserved-unstructured-28

7161-7174

0.774316

0.62504

SARS-CoV-2-conserved-unstructured-29

6010-6029

0.738649

0.624805

SARS-CoV-2-conserved-unstructured-30

6515-6529

0.81084

0.624018

SARS-CoV-2-conserved-unstructured-31

18219-18232

0.749532

0.623586

SARS-CoV-2-conserved-unstructured-32

11659-11681

0.819159

0.623162

SARS-CoV-2-conserved-unstructured-33

24778-24797

0.771131

0.622469

SARS-CoV-2-conserved-unstructured-34

21669-21683

0.788644

0.621176

SARS-CoV-2-conserved-unstructured-35

6105-6122

0.777239

0.618997

SARS-CoV-2-conserved-unstructured-36

28436-28452

0.80827

0.618884

Sequence

AUACAAUGUAACAC
CCAAUGGAAAAACUCAA
UUGUUAAAAUUUAUUG
ACUCAAUUACCCCCUGCA
CGAAUACCAUAAUGAAU
UCAAUUUAAACACC
AAUCAUCAUCUAAA
UUUAAUUUUUCACAAAUAUUAC
CAAGCUUUGUUAAA
UCUUUACCAACCACCACAAACCUCUAU
CCAUACCCACAAAUUUUAC
UAUUGAAUAUCCUAUAA
UAAACGAACAUGAAAAUU
UAAACAUAUAACUUCUA
CACAAGUCAAACAAAUUUACAAA
CUGUCUUUAUUUCACCUUAUAAUU
UUCCAAAAUCAUAA
UUACAAACAAUUUGAUACUU
UAAUAUUACAAACU
ACAAUUGGAACUGUAACUUUG
UUAAAAAGUUGAAGAA
UUGUACUAAUUAUAUGCCUUAUUUCUU
ACAACAUGUUAAAAACUGUUUA
AUAAACCUAUUGUU
UAUUCUGUUAUUUACUUGUAC
UAAUUCUUUCACAC
AUCCAUCAAAACCA
ACACCUAUCCUUCU
ACCAAACCAACCAUAUCCAA
UUAAAAAUUACAGAA
UAAAAUGAAUUAUC
UUUACUCAACCGCUACUUUAGAC
AAAGAACUUCACAACUGCUC
UUUAUUACCCUGACA
AUAAGAAACCUGCUUCAA
GCUCUCACUCAACAUGG

22

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

SARS-CoV-2-conserved-unstructured-37

16361-16375

0.772562

0.618808

SARS-CoV-2-conserved-unstructured-38

28148-28162

0.734308

0.616622

SARS-CoV-2-conserved-unstructured-39

24165-24178

0.745439

0.616288

SARS-CoV-2-conserved-unstructured-40

26429-26447

0.741331

0.615047

SARS-CoV-2-conserved-unstructured-41

6072-6086

0.727041

0.614595

SARS-CoV-2-conserved-unstructured-42

1304-1319

0.821877

0.614536

SARS-CoV-2-conserved-unstructured-43

1918-1933

0.751566

0.614279

SARS-CoV-2-conserved-unstructured-44

27361-27375

0.740696

0.61226

SARS-CoV-2-conserved-unstructured-45

28853-28866

0.770189

0.611938

SARS-CoV-2-conserved-unstructured-46

14899-14913

0.741656

0.610443

SARS-CoV-2-conserved-unstructured-47

19260-19273

0.760965

0.609632

SARS-CoV-2-conserved-unstructured-48

11724-11740

0.729639

0.607945

SARS-CoV-2-conserved-unstructured-49

29008-29023

0.779731

0.607881

SARS-CoV-2-conserved-unstructured-50

11537-11554

0.771241

0.607484

SARS-CoV-2-conserved-unstructured-51

11628-11645

0.85037

0.606842

SARS-CoV-2-conserved-unstructured-52

18681-18694

0.747334

0.605637

SARS-CoV-2-conserved-unstructured-53

7366-7384

0.723602

0.605523

SARS-CoV-2-conserved-unstructured-54

1031-1047

0.727712

0.605352

SARS-CoV-2-conserved-unstructured-55

14367-14380

0.714434

0.604803

SARS-CoV-2-conserved-unstructured-56

3797-3816

0.741669

0.60258

SARS-CoV-2-conserved-unstructured-57

22281-22296

0.741833

0.600606

SARS-CoV-2-conserved-unstructured-58

16038-16053

0.780044

0.600438

UCUUGUCUGUUAAUC
UUUUACAAUUAAUUG
AAAUGAUUGCUCAA
UUAAAAAUCUGAAUUCUUC
AAUUUGCUGAUGAUU
GAGAAUUUGACUAAAG
UCUUGAAACUGCUCAA
GAAGAGCAACCAAUG
UCAAGAAAUUCAAC
UGUAUUAAUGCUAAC
UAACCUUAACUUGC
UUAGAUAUAUGAAUUCA
UGUCACUAAGAAAUCU
AUUGUUUUUAUGUGUGUU
AUUUUUGUACUUGUUACU
CACAUGCUUUUCCA
AAUAAUUAAUCUUGUACAA
GAAAUUAAAUUGGCAAA
UUGUGCAAACUUUA
UUUGAUAAAAAUCUCUAUGA
CUUUACUUGCUUUACA
UUACCCACUUACUAAA

Table 3: SARS-CoV-2-conserved-unstructured. Top unstructured regions (ranked by minimum
unpaired probability over the interval, stretch of at least 15 nt) that overlap with conserved intervals
from SARS-CoV-2 for at least 15 nt at a 97% sequence conservation cutoff. Sequence intervals are
relative to the reference genome NC_045512.2.

23

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

Name
5´ UTR

Frameshifting
element
3´ UTR

Sequence
AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUC
GAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUG
UGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUA
AUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGU
CUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGC
CGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAG
GUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACAC
GUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCG
UACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGC
ACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUG
AAAAAGGCGUUUUGCC
GUUUUUAAACGGGUUUGCGGUGUAAGUGCAGCCCGUCUUACACCG
UGCGGCACAGGCACUAGUACUGAUGUCGUAUACAGGGCUUUUG

Secondary structure dot-bracket
......(((((.(((((....)))))..)))))...........((((
(.....))))).((((.......))))........((((((((.((.(
(((.(((.....))).)))))).))))))))(..(((((.....)))
)))...(((((((((((..(((((...(((.((((((((((((.((
((((.(((((......)))))..))))))).....)))(((((((.(
(......)))))))))(((....)))))))))))))).))))).))
))...))))))).......((((((.......((..((((((...)))
)))..))))))))(....(((((.(((((((((((((.....))))
.))))..))))).)))))...(((((...)))))).......(((((
.....)))))......(((.....)))

GACCACACAAGGCAGAUGGGCUAUAUAAACGUUUUCGCUUUUCCG
UUUACGAUAUAUAGUCUACUCUUGUGCAGAAUGAAUUCUCGUAACU
ACAUAGCACAAGUAGAUGUAGUUAACUUUAAUCUCACAUAGCAAUC
UUUAAUCAGUGUGUAACAUUAGGGAGGACUUGAAAGAGCCACCACA
UUUUCACCGAGGCCACGCGGAGUACGAUCGAGUGUACAGUGAACA
AUGCUAGGGAGAGCUGCCUAUAUGGAAGAGCCCUAAUGUGUAAAA
UUAAUUUUAGUAGUGCUAUCCCCAUGUGAUUUUAAUAGCUUCUUA
GGAGAAUGACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

................(((((((((((..(((...((......))...)
)).)))))))))))..(((((((.......{{{{{{.[[[[[[[[[.)
))))))...]]]]]]]]]...((((..((((((((((..((..(((.(
((.....(((((((((.((.(((....)))))....(((((((((..
..((..((((.....))..))...))...))))).)))).((((....
....))))..........))))))))).....))).)))..))...))
)))......)))))..))))...........}}}}}}.............
.......................

...............(((((((((((...[[[[[[[)))))))))))(
(((((((.........))).)))))...]].]]]]]....

Table 4: Sequences and secondary structure dot-brackets for key structured genome regions of
SARS-CoV-2.

24

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

References
1.
Fehr, A. R.; Perlman, S., Coronaviruses: an overview of their replication and pathogenesis.
Methods Mol. Biol. 2015, 1282, 1-23.
2.
Connelly, C. M.; Moon, M. H.; Schneekloth, J. S., Jr., The Emerging Role of RNA as a
Therapeutic Target for Small Molecules. Cell Chem Biol 2016, 23 (9), 1077-1090.
3.
Spurgers, K. B.; Sharkey, C. M.; Warfield, K. L.; Bavari, S., Oligonucleotide antiviral
therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res.
2008, 78 (1), 26-36.
4.
Bennett, C. F.; Krainer, A. R.; Cleveland, D. W., Antisense Oligonucleotide Therapies for
Neurodegenerative Diseases. Annu. Rev. Neurosci. 2019, 42, 385-406.
5.
Yang, D.; Leibowitz, J. L., The structure and functions of coronavirus genomic 3' and 5' ends.
Virus Res. 2015, 206, 120-133.
6.
van den Born, E.; Posthuma, C. C.; Gultyaev, A. P.; Snijder, E. J., Discontinuous
subgenomic RNA synthesis in arteriviruses is guided by an RNA hairpin structure located in the
genomic leader region. J. Virol. 2005, 79 (10), 6312-6324.
7.
Plant, E. P.; Dinman, J. D., The role of programmed-1 ribosomal frameshifting in coronavirus
propagation. Front. Biosci. 2008, 13, 4873-4881.
8.
Stammler, S. N.; Cao, S.; Chen, S.-J.; Giedroc, D. P., A conserved RNA pseudoknot in a
putative molecular switch domain of the 3'-untranslated region of coronaviruses is only marginally
stable. RNA 2011, 17 (9), 1747-1759.
9.
Chen, S.-C.; Olsthoorn, R. C. L., Group-specific structural features of the 5'-proximal
sequences of coronavirus genomic RNAs. Virology 2010, 401 (1), 29-41.
10.
Ceraolo, C.; Giorgi, F. M., Genomic variance of the 2019-nCoV coronavirus. J. Med. Virol.
2020, 92 (5), 522-528.
11.
Wu, F.; Zhao, S.; Yu, B.; Chen, Y.-M.; Wang, W.; Hu, Y.; Song, Z.-G.; Tao, Z.-W.; Tian, J.H.; Pei, Y.-Y.; Yuan, M. L.; Zhang, Y.-L.; Dai, F.-H.; Liu, Y.; Wang, Q.-M.; Zheng, J.-J.; Xu, L.;
Holmes, E. C.; Zhang, Y.-Z., NC_045512. Nucleotide [Internet]. Bethesda (MD): National Library of
Medicine (US), N. C. f. B. I., Ed. 2020.
12.
Viruses, C. S. G. o. T. I. C. o. T. o.; Coronaviridae Study Group of the International
Committee on Taxonomy of, V., The species Severe acute respiratory syndrome-related
coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology 2020, 5 (4),
536-544.
13.
Madhugiri, R.; Fricke, M.; Marz, M.; Ziebuhr, J., RNA structure analysis of alphacoronavirus
terminal genome regions. Virus Res. 2014, 194, 76-89.
14.
Kalvari, I.; Argasinska, J.; Quinones-Olvera, N.; Nawrocki, E. P.; Rivas, E.; Eddy, S. R.;
Bateman, A.; Finn, R. D.; Petrov, A. I., Rfam 13.0: shifting to a genome-centric resource for noncoding RNA families. Nucleic Acids Res. 2018, 46 (D1), D335-D342.
15.
Nawrocki, E. P.; Eddy, S. R., Infernal 1.1: 100-fold faster RNA homology searches.
Bioinformatics 2013, 29 (22), 2933-5.
16.
Yang, D.; Liu, P.; Wudeck, E. V.; Giedroc, D. P.; Leibowitz, J. L., SHAPE analysis of the
RNA secondary structure of the Mouse Hepatitis Virus 5' untranslated region and N-terminal nsp1
coding sequences. Virology 2015, 475, 15-27.
17.
Elbe, S.; Buckland-Merrett, G., Data, disease and diplomacy: GISAID's innovative
contribution to global health. Glob Chall 2017, 1 (1), 33-46.
18.
Do, C. B.; Woods, D. A.; Batzoglou, S., CONTRAfold: RNA secondary structure prediction
without physics-based models. Bioinformatics 2006, 22 (14), e90-8.
19.
Hamada, M.; Sato, K.; Asai, K., Prediction of RNA secondary structure by maximizing
pseudo-expected accuracy. BMC Bioinformatics 2010, 11, 586.
20.
Herold, J.; Siddell, S. G., An 'elaborated' pseudoknot is required for high frequency
frameshifting during translation of HCV 229E polymerase mRNA. Nucleic Acids Res 1993, 21 (25),
5838-42.

25

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

21.
Gruber, A. R.; Findeiß, S.; Washietl, S.; Hofacker, I. L.; Stadler, P. F., RNAz 2.0: improved
noncoding RNA detection. Pac. Symp. Biocomput. 2010, 69-79.
22.
Rivas, E.; Clements, J.; Eddy, S. R., Estimating the power of sequence covariation for
detecting conserved RNA structure. Bioinformatics 2020.
23.
Li, L.; Kang, H.; Liu, P.; Makkinje, N.; Williamson, S. T.; Leibowitz, J. L.; Giedroc, D. P.,
Structural lability in stem-loop 1 drives a 5' UTR-3' UTR interaction in coronavirus replication. J. Mol.
Biol. 2008, 377 (3), 790-803.
24.
Liu, P.; Li, L.; Millership, J. J.; Kang, H.; Leibowitz, J. L.; Giedroc, D. P., A U-turn motifcontaining stem-loop in the coronavirus 5' untranslated region plays a functional role in replication.
RNA 2007, 13 (5), 763-780.
25.
Kelly, J. A.; Dinman, J. D., Structural and functional conservation of the programmed -1
ribosomal frameshift signal of SARS-CoV-2. bioRxiv 2020.
26.
Goebel, S. J.; Hsue, B.; Dombrowski, T. F.; Masters, P. S., Characterization of the RNA
components of a putative molecular switch in the 3' untranslated region of the murine coronavirus
genome. J. Virol. 2004, 78 (2), 669-682.
27.
Goebel, S. J.; Miller, T. B.; Bennett, C. J.; Bernard, K. A.; Masters, P. S., A hypervariable
region within the 3' cis-acting element of the murine coronavirus genome is nonessential for RNA
synthesis but affects pathogenesis. J. Virol. 2007, 81 (3), 1274-1287.
28.
Robertson, M. P.; Igel, H.; Baertsch, R.; Haussler, D.; Ares, M., Jr.; Scott, W. G., The
structure of a rigorously conserved RNA element within the SARS virus genome. PLoS Biol. 2005, 3
(1), e5.
29.
Jonassen, C. M.; Jonassen, T. O.; Grinde, B., A common RNA motif in the 3' end of the
genomes of astroviruses, avian infectious bronchitis virus and an equine rhinovirus. J. Gen. Virol.
1998, 79 ( Pt 4), 715-718.
30.
Guan, B.-J.; Su, Y.-P.; Wu, H.-Y.; Brian, D. A., Genetic evidence of a long-range RNA-RNA
interaction between the genomic 5' untranslated region and the nonstructural protein 1 coding region
in murine and bovine coronaviruses. J. Virol. 2012, 86 (8), 4631-4643.
31.
Kappel, K.; Zhang, K.; Su, Z.; Kladwang, W.; Li, S.; Pintilie, G.; Topkar, V. V.; Rangan, R.;
Zheludev, I. N.; Watkins, A. M.; Yesselman, J. D.; Chiu, W.; Das, R., Ribosolve: Rapid determination
of three-dimensional RNA-only structures. bioRxiv 2019.
32.
Zhang, K.; Li, S.; Kappel, K.; Pintilie, G.; Su, Z.; Mou, T.-C.; Schmid, M. F.; Das, R.; Chiu,
W., Cryo-EM structure of a 40 kDa SAM-IV riboswitch RNA at 3.7 Å resolution. Nat. Commun. 2019,
10 (1), 5511.
33.
Edgar, R. C., MUSCLE: multiple sequence alignment with high accuracy and high
throughput. Nucleic Acids Res. 2004, 32 (5), 1792-1797.
34.
Li, W.; Jaroszewski, L.; Godzik, A., Clustering of highly homologous sequences to reduce the
size of large protein databases. Bioinformatics 2001, 17 (3), 282-283.
35.
Sievers, F.; Wilm, A.; Dineen, D.; Gibson, T. J.; Karplus, K.; Li, W.; Lopez, R.; McWilliam, H.;
Remmert, M.; Söding, J.; Thompson, J. D.; Higgins, D. G., Fast, scalable generation of high-quality
protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 2011, 7, 539.
36.
Katoh, K.; Frith, M. C., Adding unaligned sequences into an existing alignment using MAFFT
and LAST. Bioinformatics 2012, 28 (23), 3144-3146.
37.
Washietl, S.; Hofacker, I. L., Consensus folding of aligned sequences as a new measure for
the detection of functional RNAs by comparative genomics. J Mol Biol 2004, 342 (1), 19-30.
38.
Rivas, E.; Clements, J.; Eddy, S. R., A statistical test for conserved RNA structure shows
lack of evidence for structure in lncRNAs. Nat Methods 2017, 14 (1), 45-48.
39.
Cock, P. J.; Antao, T.; Chang, J. T.; Chapman, B. A.; Cox, C. J.; Dalke, A.; Friedberg, I.;
Hamelryck, T.; Kauff, F.; Wilczynski, B.; de Hoon, M. J., Biopython: freely available Python tools for
computational molecular biology and bioinformatics. Bioinformatics 2009, 25 (11), 1422-3.
40.
Bernhart, S. H.; Hofacker, I. L.; Stadler, P. F., Local RNA base pairing probabilities in large
sequences. Bioinformatics 2006, 22 (5), 614-5.
41.
Kearse, M.; Moir, R.; Wilson, A.; Stones-Havas, S.; Cheung, M.; Sturrock, S.; Buxton, S.;
Cooper, A.; Markowitz, S.; Duran, C.; Thierer, T.; Ashton, B.; Meintjes, P.; Drummond, A., Geneious

26

bioRxiv preprint doi: https://doi.org/10.1101/2020.03.27.012906; this version posted April 6, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.

Basic: an integrated and extendable desktop software platform for the organization and analysis of
sequence data. Bioinformatics 2012, 28 (12), 1647-1649.

27

